Meningococcal vaccines

Vaccines: Sixth Edition

Volumn , Issue , 2012, Pages 388-418

  Granoff, Dan M ^a   Pelton, Stephen ^b   Harrison, Lee H ^c  

^a CHILDREN S HOSPITAL OAKLAND RESEARCH INSTITUTE   (United States)

^b BOSTON UNIVERSITY   (United States)

^c UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84880831278     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4557-0090-5.00029-X     Document Type: Chapter

References (523)

1. Thigpen M.C., Whitney C.G., Messonnier N.E., et al. Bacterial meningitis in the United States, 1998-2007. N Engl J Med 2011, 364:2016-2025.
2. Maiden M.C., Ibarz-Pavon A.B., Urwin R., et al. Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity. J Infect Dis 2008, 197:737-743.
3. Updated recommendations for use of meningococcal conjugate vaccines: Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Morb Mortal Wkly Rep 2011, 60:72-76.
4. Granoff D.M. Relative importance of complement-mediated bactericidal and opsonic activity for protection against meningococcal disease. Vaccine 2009, 27(Suppl. 2):B117-B125.
5. Trotter C.L., Andrews N.J., Kaczmarski E.B., et al. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet 2004, 364:365-367.
6. Granoff D.M. Review of meningococcal group B vaccines. Clin Infect Dis 2010, 50(Suppl. 2):S54-S65.
7. Ramsay M.E., Andrews N.J., Trotter C.L., et al. Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis. BMJ 2003, 326:365-366.
8. Snape M.D., Perrett K.P., Ford K.J., et al. Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial. JAMA 2008, 299:173-184.
9. Licensure of a meningococcal conjugate vaccine for children aged 2 through 10 years and updated booster dose guidance for adolescents and other persons at increased risk for meningococcal disease: Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morb Mortal Wkly Rep 2011, 60:1018-1019.
10. LaForce F.M., Okwo-Bele J.M. Eliminating epidemic group A meningococcal meningitis in Africa through a new vaccine. Health Aff (Millwood) 2011, 30:1049-1057.
11. Findlow J., Borrow R., Snape M.D., et al. Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy. Clin Infect Dis 2010, 51:1127-1137.
12. Weichselbaum A. Ueber die aetiologie der akuten meningitis cerebro-spinal. Fortschr Med 1887, 5:573-583. 620-6.
13. Vieusseux M. Memoire sur le maladie qui a regne a Geneva au printemps de 1805. J Med Clin Pharm 1805, 11:163-182.
14. Danielson L., Mann E. A history of a singular and very noted disease, which lately made its appearance in Medfield. Medical and Agricultural Register 1806, 1:65-69.
15. Greenwood B. Manson lecture: meningococcal meningitis in Africa. Trans R Soc Trop Med Hyg 1999, 93:341-353.
16. Flexner S. The results of the serum treatment in thirteen hundred cases of epidemic meningitis. J Exp Med 1913, 17:553.
17. Caron F., du Châtelet I.P., Leroy J.P., et al. From tailor-made to ready-to-wear meningococcal B vaccines: longitudinal study of a clonal meningococcal B outbreak [published online ahead of print April 12, 2011]. Lancet Infect Dis 2011, 11:455-463.
18. Kaplan S.L., Schutze G.E., Leake J.A., et al. Multicenter surveillance of invasive meningococcal infections in children. Pediatrics 2006, 118:e979-e984.
19. Thompson M.J., Ninis N., Perera R., et al. Clinical recognition of meningococcal disease in children and adolescents. Lancet 2006, 367:397-403.
20. Thigpen M.C., Whitney C.G., Messonnier N.E., et al. Bacterial meningitis in the United States, 1998-2007. N Engl J Med 2011, 364:2016-2025.
21. Rosenstein N.E., Perkins B.A., Stephens D.S., et al. Meningococcal disease. N Engl J Med 2001, 344:1378-1388.
22. Winstead J.M., McKinsey D.S., Tasker S., et al. Meningococcal pneumonia: characterization and review of cases seen over the past 25 years. Clin Infect Dis 2000, 30:87-94.
23. Sparling P.F. A plethora of host factors that determine the outcome of meningococcal infection. Am J Med 2002, 112:72-74.
24. Erickson L.J., De Wals P., McMahon J., et al. Complications of meningococcal disease in college students. Clin Infect Dis 2001, 33:737-739.
25. Fellick J.M., Sills J.A., Marzouk O., et al. Neurodevelopmental outcome in meningococcal disease: a case-control study. Arch Dis Child 2001, 85:6-11.
26. Erickson L., De Wals P. Complications and sequelae of meningococcal disease in Quebec, Canada, 1990-1994. Clin Infect Dis 1998, 26:1159-1164.
27. Edwards M.S., Baker C.J. Complications and sequelae of meningococcal infections in children. J Pediatr 1981, 99:540-545.
28. Canavese F., Krajbich J.I., LaFleur B.J. Orthopaedic sequelae of childhood meningococcemia: management considerations and outcome. J Bone Joint Surg Am 2010, 92:2196-2203.
29. Dodge P.R., Davis H., Feigin R.D., et al. Prospective evaluation of hearing impairment as a sequela of acute bacterial meningitis. N Engl J Med 1984, 311:869-874.
30. Dodge P.R., Scaer M., Holmes S.J., et al. Psychometric testing in bacterial meningitis: results of a long-term prospective study of infants and children treated between 1973 and 1977. J Child Neurol 2001, 16:854-857.
31. Edmond K., Dieye Y., Griffiths U.K., et al. Prospective cohort study of disabling sequelae and quality of life in children with bacterial meningitis in urban Senegal. Pediatr Infect Dis J 2010, 29:1023-1029.
32. Knapp J.S., Koumans E.H. Neisseria and Branhamella. Manual of Clinical Microbiology 2007, 586-603. ASM Press, Washington, DC. 9th ed. P.R. Murray, E.J. Baron, J.H. Jorgensen (Eds.).
33. Fu J., Bailey F.J., King J.J., et al. Recent advances in the large scale fermentation of Neisseria meningitidis group B for the production of an outer membrane protein complex. Biotechnology (N Y) 1995, 13:170-174.
34. Frantz I.D. Growth requirements of the meningococcus. J Bacteriol 1942, 43:757-761.
35. Branham S.E. Serological relationships among meningococci. Bacteriol Rev 1953, 17:175-188.
36. Vedros N.A. Development of meningococcal serogroups. Evolution of Meningococcal Disease 1987, 33-37. CRC Press, Boca Raton, FL. N.A. Vedros (Ed.).
37. Harrison L.H., Trotter C.L., Ramsay M.E. Global epidemiology of meningococcal disease. Vaccine 2009, 27(Suppl. 2):B51-B63.
38. Tsai C.M., Frasch C.E., Mocca L.F. Five structural classes of major outer membrane proteins in Neisseria meningitidis. J Bacteriol 1981, 146:69-78.
39. Frasch C.E., Zollinger W.D., Poolman J.T. Serotype antigens of Neisseria meningitidis and a proposed scheme for designation of serotypes. Rev Infect Dis 1985, 7:504-510.
40. Abdillahi H., Poolman J.T. Typing of group-B Neisseria meningitidis with monoclonal antibodies in the whole-cell ELISA. J Med Microbiol 1988, 26:177-180.
41. Abdillahi H., Poolman J.T. Neisseria meningitidis group B serosubtyping using monoclonal antibodies in whole-cell ELISA. Microb Pathog 1988, 4:27-32.
42. Abdillahi H., Poolman J.T. Definition of meningococcal class 1 OMP subtyping antigens by monoclonal antibodies. FEMS Microbiol Immunol 1988, 1:139-144.
43. Maiden M.C., Russell J., Suker J., et al. Neisseria meningitidis subtype nomenclature. Clin Diagn Lab Immunol 1999, 6:771-772.
44. Maiden M.C., Feavers I.M. Meningococcal typing. J Med Microbiol 1994, 40:157-158.
45. Thompson E.A., Feavers I.M., Maiden M.C. Antigenic diversity of meningococcal enterobactin receptor FetA, a vaccine component. Microbiology 2003, 149(pt 7):1849-1858.
46. Harrison L.H., Jolley K.A., Shutt K.A., et al. Antigenic shift and increased incidence of meningococcal disease. J Infect Dis 2006, 193:1266-1274.
47. Beernink P.T., Granoff D.M. The modular architecture of meningococcal factor H-binding protein. Microbiology 2009, 155(pt 9):2873-2883.
48. Pajon R., Beernink P.T., Harrison L.H., et al. Frequency of factor H-binding protein modular groups and susceptibility to cross-reactive bactericidal activity in invasive meningococcal isolates. Vaccine 2010, 28:2122-2129.
49. Lucidarme J., Newbold L.S., Findlow J., et al. Molecular targets in meningococci: efficient routine characterization and optimal outbreak investigation in conjunction with routine surveillance of the meningococcal group B vaccine candidate, fHBP. Clin Vaccine Immunol 2011, 18:194-202.
50. Scholten R.J., Kuipers B., Valkenburg H.A., et al. Lipo-oligosaccharide immunotyping of Neisseria meningitidis by a whole-cell ELISA with monoclonal antibodies. J Med Microbiol 1994, 41:236-243.
51. Smith J.M., Dowson C.G., Spratt B.G. Localized sex in bacteria. Nature 1991, 349:29-31.
52. Davidsen T., Tonjum T. Meningococcal genome dynamics. Nat Rev Microbiol 2006, 4:11-22.
53. Maiden M.C.J, Feavers I.M. Population genetics and global epidemiology of the human pathogen Neisseria meningitidis. Population Genetics of Bacteria 1995, 269-293. Cambridge University Press, Cambridge. S. Baumberg, J.P.W. Young, J.R. Suanders (Eds.).
54. Caugant D.A., Mocca L.F., Frasch C.E., et al. Genetic structure of Neisseria meningitidis populations in relation to serogroup, serotype, and outer membrane protein pattern. J Bacteriol 1987, 169:2781-2792.
55. Feavers I.M., Heath A.B., Bygraves J.A., et al. Role of horizontal genetic exchange in the antigenic variation of the class 1 outer membrane protein of Neisseria meningitidis. Mol Microbiol 1992, 6:489-495.
56. Wang J.F., Caugant D.A., Morelli G., et al. Antigenic and epidemiologic properties of the ET-37 complex of Neisseria meningitidis. J Infect Dis 1993, 167:1320-1329.
57. Harrison L.H., Shutt K.A., Schmink S.E., et al. Population structure and capsular switching of invasive Neisseria meningitidis isolates in the pre-meningococcal conjugate vaccine era: United States, 2000-2005. J Infect Dis 2010, 201:1208-1224.
58. Maiden M.C., Bygraves J.A., Feil E., et al. Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenic microorganisms. Proc Natl Acad Sci U S A 1998, 95:3140-3145.
59. Maiden M.C. Multilocus sequence typing of bacteria. Annu Rev Microbiol 2006, 60:561-588.
60. Budroni S., Siena E., Hotopp J.C., et al. Neisseria meningitidis is structured in clades associated with restriction modification systems that modulate homologous recombination. Proc Natl Acad Sci U S A 2011, 108:4494-4499.
61. Parkhill J., Achtman M., James K.D., et al. Complete DNA sequence of a serogroup A strain of Neisseria meningitidis Z2491. Nature 2000, 404:502-506.
62. Peng J., Yang L., Yang F., et al. Characterization of ST-4821 complex, a unique Neisseria meningitidis clone. Genomics 2008, 91:78-87.
63. Tettelin H., Saunders N.J., Heidelberg J., et al. Complete genome sequence of Neisseria meningitidis serogroup B strain MC58. Science 2000, 287:1809-1815.
64. Rusniok C., Vallenet D., Floquet S., et al. NeMeSys: a biological resource for narrowing the gap between sequence and function in the human pathogen Neisseria meningitidis. Genome Biol 2009, 10:R110.
65. Bentley S.D., Vernikos G.S., Snyder L.A., et al. Meningococcal genetic variation mechanisms viewed through comparative analysis of serogroup C strain FAM18. PLoS Genet 2007, 3:e23. doi:10.1371/journal.pgen.0030023.
66. Schoen C., Blom J., Claus H., et al. Whole-genome comparison of disease and carriage strains provides insights into virulence evolution in Neisseria meningitidis. Proc Natl Acad Sci U S A 2008, 105:3473-3478.
67. Schoen C., Weber-Lehmann J., Blom J., et al. Whole-genome sequence of the transformable Neisseria meningitidis serogroup A strain WUE2594 [published online ahead of print February 4, 2011]. J Bacteriol 2011, 193:2064-2065. doi:10.1128/ JB.00084-11.
68. Bennett J.S., Bentley S.D., Vernikos G.S., et al. Independent evolution of the core and accessory gene sets in the genus Neisseria: insights gained from the genome of Neisseria lactamica isolate 020-06. BMC Genomics 2010, 11:652. doi:10.1186/1471-2164-11-652.
69. Snyder L.A., Butcher S.A., Saunders N.J. Comparative whole-genome analyses reveal over 100 putative phase-variable genes in the pathogenic Neisseria spp. Microbiology 2001, 147(pt 8):2321-2332.
70. Kellerman S.E., McCombs K., Ray M., et al. Genotype-specific carriage of Neisseria meningitidis in Georgia counties with hyper- and hyposporadic rates of meningococcal disease. J Infect Dis 2002, 186:40-48.
71. Clark T.A., Stern E., Pondo T., et al. The effect of quadrivalent (A, C, Y, W-135) meningococcal conjugate vaccine on serogroup-specific carriage of Neisseria meningitidis 2008.
72. Maiden M.C., Ibarz-Pavon A.B., Urwin R., et al. Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity. J Infect Dis 2008, 197:737-743.
73. Cartwright K.A., Stuart J.M., Jones D.M., et al. The Stonehouse survey: nasopharyngeal carriage of meningococci and Neisseria lactamica. Epidemiol Infect 1987, 99:591-601.
74. Caugant D.A., Hoiby E.A., Magnus P., et al. Asymptomatic carriage of Neisseria meningitidis in a randomly sampled population. J Clin Microbiol 1994, 32:323-330.
75. Kristiansen P.A., Diomande F., Wei S.C., et al. Baseline meningococcal carriage in Burkina Faso before the introduction of a meningococcal serogroup A conjugate vaccine. Clin Vaccine Immunol 2011, 18:435-443.
76. Christensen H., May M., Bowen L., et al. Meningococcal carriage by age: a systematic review and meta-analysis. Lancet Infect Dis 2010, 10:853-861.
77. Cartwright K.A., Jones D.M., Smith A.J., et al. Influenza A and meningococcal disease. Lancet 1991, 338:554-557.
78. Young L.S., LaForce F.M., Head J.J., et al. A simultaneous outbreak of meningococcal and influenza infections. N Engl J Med 1972, 287:5-9.
79. Harrison L.H., Armstrong C.W., Jenkins S.R., et al. A cluster of meningococcal disease on a school bus following epidemic influenza. Arch Intern Med 1991, 151:1005-1009.
80. Tuite A.R., Kinlin L.M., Kuster S.P., et al. Respiratory virus infection and risk of invasive meningococcal disease in central Ontario. Canada. PLoS One 2010, 5:e15493. doi:10.1371/journal.pone.0015493.
81. Fischer M., Hedberg K., Cardosi P., et al. Tobacco smoke as a risk factor for meningococcal disease. Pediatr Infect Dis J 1997, 16:979-983.
82. MacLennan J., Kafatos G., Neal K., et al. Social behavior and meningococcal carriage in British teenagers. Emerg Infect Dis 2006, 12:950-957.
83. Lee C.C., Middaugh N.A., Howie S.R., et al. Association of secondhand smoke exposure with pediatric invasive bacterial disease and bacterial carriage: a systematic review and meta-analysis. PLoS Med 2010, 7:e1000374. doi:10.1371/journal.pmed.1000374.
84. Hodgson A., Smith T., Gagneux S., et al. Risk factors for meningococcal meningitis in northern Ghana. Trans R Soc Trop Med Hyg 2001, 95:477-480.
85. Imrey P.B., Jackson L.A., Ludwinski P.H., et al. Outbreak of serogroup C meningococcal disease associated with campus bar patronage. Am J Epidemiol 1996, 143:624-630.
86. Imrey P.B., Jackson L.A., Ludwinski P.H., et al. Meningococcal carriage, alcohol consumption, and campus bar patronage in a serogroup C meningococcal disease outbreak. J Clin Microbiol 1995, 33:3133-3137.
87. Bogaert D., Hermans P.W., Boelens H., et al. Epidemiology of nasopharyngeal carriage of Neisseria meningitidis in healthy Dutch children. Clin Infect Dis 2005, 40:899-902.
88. Harrison L.H., Kreiner C.J., Shutt K.A., et al. Risk factors for meningococcal disease in students in grades 9-12. Pediatr Infect Dis J 2008, 27:193-199.
89. Tully J., Viner R.M., Coen P.G., et al. Risk and protective factors for meningococcal disease in adolescents: matched cohort study. BMJ 2006, 332:445-450. doi:10.1136/bmj.38725.728472.BE.
90. Nelson S.J., Charlett A., Orr H.J., et al. Risk factors for meningococcal disease in university halls of residence. Epidemiol Infect 2001, 126:211-217.
91. Cohen C., Singh E., Wu H.M., et al. Increased incidence of meningococcal disease in HIV-infected individuals associated with higher case-fatality ratios in South Africa. AIDS 2010, 24:1351-1360.
92. Caugant D.A., Maiden M.C. Meningococcal carriage and disease: population biology and evolution. Vaccine 2009, 27(Suppl. 2):B64-B70.
93. Hoang L.M., Thomas E., Tyler S., et al. Rapid and fatal meningococcal disease due to a strain of Neisseria meningitidis containing the capsule null locus. Clin Infect Dis 2005, 40:e38-e42.
94. Vogel U., Claus H., von Muller L., et al. Bacteremia in an immunocompromised patient caused by a commensal Neisseria meningitidis strain harboring the capsule null locus (cnl). J Clin Microbiol 2004, 42:2898-2901.
95. Bonnah R.A., Hoelter J., Steeghs L., et al. Lipooligosaccharide-independent alteration of cellular homeostasis in Neisseria meningitidis-infected epithelial cells. Cell Microbiol 2005, 7:869-885.
96. Helaine S., Carbonnelle E., Prouvensier L., et al. PilX, a pilus-associated protein essential for bacterial aggregation, is a key to pilus-facilitated attachment of Neisseria meningitidis to human cells. Mol Microbiol 2005, 55:65-77.
97. Nassif X. Interaction mechanisms of encapsulated meningococci with eucaryotic cells: what does this tell us about the crossing of the blood-brain barrier by Neisseria meningitidis?. Curr Opin Microbiol 1999, 2:71-77.
98. Muenzner P., Dehio C., Fujiwara T., et al. Carcinoembryonic antigen family receptor specificity of Neisseria meningitidis Opa variants influences adherence to and invasion of proinflammatory cytokine-activated endothelial cells. Infect Immun 2000, 68:3601-3607.
99. Eugene E., Hoffmann I., Pujol C., et al. Microvilli-like structures are associated with the internalization of virulent capsulated Neisseria meningitidis into vascular endothelial cells. J Cell Sci 2002, 115(pt 6):1231-1241.
100. Goldschneider I., Gotschlich E.C., Artenstein M.S. Human immunity to the meningococcus, I: the role of humoral antibodies. J Exp Med 1969, 129:1307-1326.
101. Condon R.J., Riley T.V., Kelly H. Invasive meningococcal infection after splenectomy. BMJ 1994, 308:792-793.
102. Pollard A.J., Frasch C. Development of natural immunity to Neisseria meningitidis. Vaccine 2001, 19:1327-1346.
103. Schlesinger M., Nave Z., Levy Y., et al. Prevalence of hereditary properdin, C7 and C8 deficiencies in patients with meningococcal infections. Clin Exp Immunol 1990, 81:423-427.
104. Fijen C.A., Kuijper E.J., Tjia H.G., et al. Complement deficiency predisposes for meningitis due to nongroupable meningococci and Neisseria-related bacteria. Clin Infect Dis 1994, 18:780-784.
105. Fijen C.A., Kuijper E.J., te Bulte M.T., et al. Assessment of complement deficiency in patients with meningococcal disease in the Netherlands. Clin Infect Dis 1999, 28:98-105.
106. Linton S.M., Morgan B.P. Properdin deficiency and meningococcal disease: identifying those most at risk. Clin Exp Immunol 1999, 118:189-191.
107. Nicholson A., Lepow I.H. Host defense against Neisseria meningitidis requires a complement-dependent bactericidal activity. Science 1979, 205:298-299.
108. Nielsen H.E., Koch C., Magnussen P., et al. Complement deficiencies in selected groups of patients with meningococcal disease. Scand J Infect Dis 1989, 21:389-396.
109. Mathew S., Overturf G.D. Complement and properidin deficiencies in meningococcal disease. Pediatr Infect Dis J 2006, 25:255-256.
110. Ram S., Lewis L.A., Rice P.A. Infections of people with complement deficiencies and patients who have undergone splenectomy. Clin Microbiol Rev 2010, 23:740-780.
111. Schneider M.C., Exley R.M., Chan H., et al. Functional significance of factor H binding to Neisseria meningitidis. J Immunol 2006, 176:7566-7575.
112. Madico G., Welsch J.A., Lewis L.A., et al. The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance. J Immunol 2006, 177:501-510.
113. Lewis L.A., Ngampasutadol J., Wallace R., et al. The meningococcal vaccine candidate neisserial surface protein A (NspA) binds to factor H and enhances meningococcal resistance to complement. PLoS Pathog 2010, 6:e1001027. doi:10.1371/journal.ppat.1001027.
114. Davila S., Wright V.J., Khor C.C., et al. Genome-wide association study identifies variants in the CFH region associated with host susceptibility to meningococcal disease. Nat Genet 2010, 42:772-776.
115. Stephens D.S., Zimmer S.M. Pathogenesis, therapy, and prevention of meningococcal sepsis. Curr Infect Dis Rep 2002, 4:377-386.
116. Brandtzaeg P., van Deuren M. Meningococcal infections at the start of the 21st century. Adv Pediatr 2005, 52:129-162.
117. Brandtzaeg P., Mollnes T.E., Kierulf P. Complement activation and endotoxin levels in systemic meningococcal disease. J Infect Dis 1989, 160:58-65.
118. Stephens D.S., Hajjeh R.A., Baughman W.S., et al. Sporadic meningococcal disease in adults: results of a 5-year population-based study. Ann Intern Med 1995, 123:937-940.
119. Schneider M.C., Exley R.M., Ram S., et al. Interactions between Neisseria meningitidis and the complement system. Trends Microbiol 2007, 15:233-240.
120. Agarwal S., Ferreira V.P., Cortes C., et al. An evaluation of the role of properdin in alternative pathway activation on Neisseria meningitidis and Neisseria gonorrhoeae. J Immunol 2010, 185:507-516.
121. Bax W.A., Cluysenaer O.J., Bartelink A.K., et al. Association of familial deficiency of mannose-binding lectin and meningococcal disease. Lancet 1999, 354:1094-1095.
122. Hibberd M.L., Sumiya M., Summerfield J.A., et al. Association of variants of the gene for mannose-binding lectin with susceptibility to meningococcal disease. Meningococcal Research Group. Lancet 1999, 353:1049-1053.
123. Jack D.L., Lee M.E., Turner M.W., et al. Mannose-binding lectin enhances phagocytosis and killing of Neisseria meningitidis by human macrophages. J Leukoc Biol 2005, 77:328-336.
124. Estabrook M.M., Jack D.L., Klein N.J., et al. Mannose-binding lectin binds to two major outer membrane proteins, opacity protein and porin, of Neisseria meningitidis. J Immunol 2004, 172:3784-3792.
125. Jack D.L., Dodds A.W., Anwar N., et al. Activation of complement by mannose-binding lectin on isogenic mutants of Neisseria meningitidis serogroup B. J Immunol 1998, 160:1346-1353.
126. Jack D.L., Jarvis G.A., Booth C.L., et al. Mannose-binding lectin accelerates complement activation and increases serum killing of Neisseria meningitidis serogroup C. J Infect Dis 2001, 184:836-845.
127. Smirnova I., Mann N., Dols A., et al. Assay of locus-specific genetic load implicates rare Toll-like receptor 4 mutations in meningococcal susceptibility. Proc Natl Acad Sci U S A 2003, 100:6075-6080.
128. van der Pol W.L., Huizinga T.W., Vidarsson G., et al. Relevance of Fcgamma receptor and interleukin-10 polymorphisms for meningococcal disease. J Infect Dis 2001, 184:1548-1555.
129. Fijen C.A., Bredius R.G., Kuijper E.J., et al. The role of Fcgamma receptor polymorphisms and C3 in the immune defence against Neisseria meningitidis in complement-deficient individuals. Clin Exp Immunol 2000, 120:338-345.
130. Platonov A.E., Shipulin G.A., Vershinina I.V., et al. Association of human Fc gamma RIIa (CD32) polymorphism with susceptibility to and severity of meningococcal disease. Clin Infect Dis 1998, 27:746-750.
131. Platonov A.E., Kuijper E.J., Vershinina I.V., et al. Meningococcal disease and polymorphism of FcgammaRIIa (CD32) in late complement component-deficient individuals. Clin Exp Immunol 1998, 111:97-101.
132. Domingo P., Muniz-Diaz E., Baraldes M.A., et al. Associations between Fc gamma receptor IIA polymorphisms and the risk and prognosis of meningococcal disease. Am J Med 2002, 112:19-25.
133. Read R.C., Camp N.J., di Giovine F.S., et al. An interleukin-1 genotype is associated with fatal outcome of meningococcal disease. J Infect Dis 2000, 182:1557-1560.
134. Westendorp R.G., Langermans J.A., Huizinga T.W., et al. Genetic influence on cytokine production in meningococcal disease. Lancet 1997, 349:1912-1913.
135. Nadel S., Newport M.J., Booy R., et al. Variation in the tumor necrosis factor-alpha gene promoter region may be associated with death from meningococcal disease. J Infect Dis 1996, 174:878-880.
136. Harding D., Baines P.B., Brull D., et al. Severity of meningococcal disease in children and the angiotensin-converting enzyme insertion/deletion polymorphism. Am J Respir Crit Care Med 2002, 165:1103-1106.
137. Chanteau S., Nato F. Rapid diagnosis of outbreak-prone bacterial diseases [in French]. Med Mal Infect 2005, 35(Suppl. 2):S100-S102.
138. Cartwright K., Reilly S., White D., et al. Early treatment with parenteral penicillin in meningococcal disease. BMJ 1992, 305:143-147.
139. Taha M.K., Alonso J.M., Cafferkey M., et al. Interlaboratory comparison of PCR-based identification and genogrouping of Neisseria meningitidis. J Clin Microbiol 2005, 43:144-149.
140. Mothershed E.A., Sacchi C.T., Whitney A.M., et al. Use of real-time PCR to resolve slide agglutination discrepancies in serogroup identification of Neisseria meningitidis. J Clin Microbiol 2004, 42:320-328.
141. Bennett D.E., Mulhall R.M., Cafferkey M.T. PCR-based assay for detection of Neisseria meningitidis capsular serogroups 29E, X, and Z. J Clin Microbiol 2004, 42:1764-1765.
142. Gray S., Campbell H., Marsh J., et al. The epidemiology and surveillance of meningococcal disease in England and Wales 2010.
143. Gray S.J., Borrow R., Kaczmarski E. Meningococcal serology. Meningococcal Disease Methods in Molecular Medicine 2001, 289-304. Humana Press, Totowa NJ. A.J. Pollard, M.C. Maiden (Eds.).
144. Sacchi C.T., Fukasawa L.O., Goncalves M.G., et al. Incorporation of real-time PCR into routine public health surveillance of culture negative bacterial meningitis in São Paulo. Brazil. PLoS One 2011, 6:e20675. doi:10.1371/journal.pone.0020675.
145. Jackson L.A., Tenover F.C., Baker C., et al. Prevalence of Neisseria meningitidis relatively resistant to penicillin in the United States, 1991. Meningococcal Disease Study Group. J Infect Dis 1994, 169:438-441.
146. Bertrand S., Carion F., Wintjens R., et al. Evolutionary Changes in Antimicrobial resistance of invasive Neisseria meningitidis isolates in Belgium from 2000 to 2010. Increasing prevalence of penicillin-non-susceptibility. Antimicrob Agents Chemother 2012, 56:2268-2272.
147. Guidelines for public health management of meningococcal disease in the UK. Commun Dis Public Health 2002, 5:187-204.
148. Jolly K., Stewart G. Epidemiology and diagnosis of meningitis: results of a five-year prospective, population-based study. Commun Dis Public Health 2001, 4:124-129.
149. Galimand M., Gerbaud G., Guibourdenche M., et al. High-level chloramphenicol resistance in Neisseria meningitidis. N Engl J Med 1998, 339:868-874.
150. Nathan N., Borel T., Djibo A., et al. Ceftriaxone as effective as long-acting chloramphenicol in short-course treatment of meningococcal meningitis during epidemics: a randomised non-inferiority study. Lancet 2005, 366:308-313.
151. Hackett S.J., Thomson A.P., Hart C.A. Cytokines, chemokines and other effector molecules involved in meningococcal disease. J Med Microbiol 2001, 50:847-859.
152. Powars D., Larsen R., Johnson J., et al. Epidemic meningococcemia and purpura fulminans with induced protein C deficiency. Clin Infect Dis 1993, 17:254-261.
153. Bernard G.R., Vincent J.L., Laterre P.F., et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001, 344:699-709.
154. Alberio L., Lammle B., Esmon C.T. Protein C replacement in severe meningococcemia: rationale and clinical experience. Clin Infect Dis 2001, 32:1338-1346.
155. Fijnvandraat K., Derkx B., Peters M., et al. Coagulation activation and tissue necrosis in meningococcal septic shock: severely reduced protein C levels predict a high mortality. Thromb Haemost 1995, 73:15-20.
156. Smith O.P., White B., Vaughan D., et al. Use of protein-C concentrate, heparin, and haemodiafiltration in meningococcus-induced purpura fulminans. Lancet 1997, 350:1590-1593.
157. White B., Livingstone W., Murphy C., et al. An open-label study of the role of adjuvant hemostatic support with protein C replacement therapy in purpura fulminans-associated meningococcemia. Blood 2000, 96:3719-3724.
158. Abraham E., Laterre P.F., Garg R., et al. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med 2005, 353:1332-1341.
159. Nadel S., Goldstein B., Williams M.D., et al. Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial. Lancet 2007, 369:836-843.
160. Levin M., Quint P.A., Goldstein B., et al. Recombinant bactericidal/permeability-increasing protein (rBPI21) as adjunctive treatment for children with severe meningococcal sepsis: a randomised trial. rBPI21 Meningococcal Sepsis Study Group. Lancet 2000, 356:961-967.
161. Giroir B.P., Scannon P.J., Levin M. Bactericidal/permeability-increasing protein: lessons learned from the phase III, randomized, clinical trial of rBPI21 for adjunctive treatment of children with severe meningococcemia. Crit Care Med 2001, 29(7 Suppl.):S130-S135.
162. de Gans J., van de Beek D. Dexamethasone in adults with bacterial meningitis. N Engl J Med 2002, 347:1549-1556.
163. Minneci P.C., Deans K.J., Banks S.M., et al. Meta-analysis: the effect of steroids on survival and shock during sepsis depends on the dose. Ann Intern Med 2004, 141:47-56.
164. Luce J.M. Physicians should administer low-dose corticosteroids selectively to septic patients until an ongoing trial is completed. Ann Intern Med 2004, 141:70-72.
165. Sprung C.L., Goodman S., Weiss Y.G. Steroid therapy of septic shock. Crit Care Nurs Clin North Am 2011, 23:171-180.
166. Centers for Disease Control and Prevention Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2000, 49(RR-7):1-10.
167. Boutet R., Stuart J.M., Kaczmarski E.B., et al. Risk of laboratory-acquired meningococcal disease. J Hosp Infect 2001, 49:282-284.
168. Sejvar J.J., Johnson D., Popovic T., et al. Assessing the risk of laboratory-acquired meningococcal disease. J Clin Microbiol 2005, 43:4811-4814.
169. Bilukha O.O., Rosenstein N. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2005, 54(RR 7):1-21. Centers for Disease Control and Prevention.
170. Emergence of fluoroquinolone-resistant Neisseria meningitidis: Minnesota and North Dakota, 2007-2008. MMWR Morb Mortal Wkly Rep 2008, 57:173-175.
171. Wu H.M., Harcourt B.H., Hatcher C.P., et al. Emergence of ciprofloxacin-resistant Neisseria meningitidis in North America. N Engl J Med 2009, 360:886-892.
172. Harrison L.H., Pelton S.I., Wilder-Smith A., et al. The Global Meningococcal Initiative: recommendations for reducing the global burden of meningococcal disease. Vaccine 2011, 29:3363-3371.
173. Vyse A., Wolter J.M., Chen J., et al. Meningococcal disease in Asia: an under-recognized public health burden. Epidemiol Infect 2011, 139:967-985. doi:10.1017/S0950268811000574.
174. Cohn A.C., MacNeil J.R., Harrison L.H., et al. Changes in Neisseria meningitidis disease epidemiology in the United States, 1998-2007: implications for prevention of meningococcal disease. Clin Infect Dis 2010, 50:184-191.
175. Updated recommendations for use of meningococcal conjugate vaccines: Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Morb Mortal Wkly Rep 2011, 60:72-76.
176. Bruce M.G., Rosenstein N.E., Capparella J.M., et al. Risk factors for meningococcal disease in college students. JAMA 2001, 286:688-693.
177. Harrison L.H., Dwyer D.M., Maples C.T., et al. Risk of meningococcal infection in college students. JAMA 1999, 281:1906-1910.
178. Neal K.R., Nguyen-Van-Tam J., Monk P., et al. Invasive meningococcal disease among university undergraduates: association with universities providing relatively large amounts of catered hall accommodation. Epidemiol Infect 1999, 122:351-357.
179. Harrison L.H., Pass M.A., Mendelsohn A.B., et al. Invasive meningococcal disease in adolescents and young adults. JAMA 2001, 286:694-699.
180. Roberts L. Hitting early, epidemic meningitis ravages Nigeria and Niger. Science 2009, 324:20-21.
181. Counts G.W., Gregory D.F., Spearman J.G., et al. Group A meningococcal disease in the U.S. Pacific Northwest: epidemiology, clinical features, and effect of a vaccination control program. Rev Infect Dis 1984, 6:640-648.
182. Makela P.H., Kayhty H., Weckstrom P., et al. Effect of group-A meningococcal vaccine in army recruits in Finland. Lancet 1975, 2:883-886.
183. Peltola H., Makela P.H., Elo O., et al. Vaccination against meningococcal group A disease in Finland 1974-75. Scand J Infect Dis 1976, 8:169-174.
184. Achtman M., van der Ende A., Zhu P., et al. Molecular epidemiology of serogroup a meningitis in Moscow, 1969 to 1997. Emerg Infect Dis 2001, 7:420-427.
185. Mironov K.O., Platonov A.E., Koroleva I.S., et al. Genetic subgroups of Neisseria meningitidis serogroup A isolated from patients with disseminated forms of meningococcal infection in Moscow, 1969-2006 [in Russian]. Zh Mikrobiol Epidemiol Immunobiol 2008, 7-12. January-February.
186. Outbreak news Meningococcal disease, Chad. Wkly Epidemiol Rec 2011, 86:101.
187. Mueller J.E., Gessner B.D. A hypothetical explanatory model for meningococcal meningitis in the African meningitis belt. Int J Infect Dis 2010, 14:e553-e559.
188. Olyhoek T., Crowe B.A., Achtman M. Clonal population structure of Neisseria meningitidis serogroup A isolated from epidemics and pandemics between 1915 and 1983. Rev Infect Dis 1987, 9:665-692.
189. Wang J.F., Caugant D.A., Li X., et al. Clonal and antigenic analysis of serogroup A Neisseria meningitidis with particular reference to epidemiological features of epidemic meningitis in the People's Republic of China. Infect Immun 1992, 60:5267-5282.
190. Bjorvatn B., Hassan-King M., Greenwood B., et al. DNA fingerprinting in the epidemiology of African serogroup A Neisseria meningitidis. Scand J Infect Dis 1992, 24:323-332.
191. Guibourdenche M., Hoiby E.A., Riou J.Y., et al. Epidemics of serogroup A Neisseria meningitidis of subgroup III in Africa, 1989-94. Epidemiol Infect 1996, 116:115-120.
192. Caugant D.A., Froholm L.O., Bovre K., et al. Intercontinental spread of a genetically distinctive complex of clones of Neisseria meningitidis causing epidemic disease. Proc Natl Acad Sci U S A 1986, 83:4927-4931.
193. Diermayer M., Hedberg K., Hoesly F., et al. Epidemic serogroup B meningococcal disease in Oregon: the evolving epidemiology of the ET-5 strain. JAMA 1999, 281:1493-1497.
194. Baker M.G., Martin D.R., Kieft C.E., et al. A 10-year serogroup B meningococcal disease epidemic in New Zealand: descriptive epidemiology, 1991-2000. J Paediatr Child Health 2001, 37:S13-S19.
195. Galloway Y., Stehr-Green P., McNicholas A., et al. Use of an observational cohort study to estimate the effectiveness of the New Zealand group B meningococcal vaccine in children aged under 5 years. Int J Epidemiol 2009, 38:413-418.
196. Loring B.J., Turner N., Petousis-Harris H. MeNZB vaccine and epidemic control: when do you stop vaccinating?. Vaccine 2008, 26:5899-5904.
197. Artenstein M.S., Schneider H., Tingley M.D. Meningococcal infections, 1: prevalence of serogroups causing disease in US Army personnel in 1964-70. Bull World Health Organ 1971, 45:275-278.
198. Souza de Morais J., Munford R.S., Risi J.B., et al. Epidemic disease due to serogroup C Neisseria meningitidis in São Paulo, Brazil. J Infect Dis 1974, 129:568-571.
199. de Lemos A.P., Yara T.Y., Gorla M.C., et al. Clonal distribution of invasive Neisseria meningitidis serogroup C strains circulating from 1976 to 2005 in greater São Paulo, Brazil. J Clin Microbiol 2007, 45:1266-1273.
200. Berron S., De La Fuente L., Martin E., et al. Increasing incidence of meningococcal disease in Spain associated with a new variant of serogroup C. Eur J Clin Microbiol Infect Dis 1998, 17:85-89.
201. Whalen C.M., Hockin J.C., Ryan A., et al. The changing epidemiology of invasive meningococcal disease in Canada, 1985 through 1992. Emergence of a virulent clone of Neisseria meningitidis. JAMA 1995, 273:390-394.
202. Ashton F.E., Ryan J.A., Borczyk A., et al. Emergence of a virulent clone of Neisseria meningitidis serotype 2a that is associated with meningococcal group C disease in Canada. J Clin Microbiol 1991, 29:2489-2493.
203. Krizova P., Musilek M. Changing epidemiology of meningococcal invasive disease in the Czech republic caused by new clone Neisseria meningitidis C:2a:P1.2(P1.5), ET-15/37. Cent Eur J Public Health 1995, 3:189-194.
204. Ramsay M., Kaczmarski E., Rush M., et al. Changing patterns of case ascertainment and trends in meningococcal disease in England and Wales. Commun Dis Rep CDR Rev 1997, 7:R49-R54.
205. Smilack J.D. Group-Y meningococcal disease. Twelve cases at an army training center. Ann Intern Med 1974, 81:740-745.
206. Koppes G.M., Ellenbogen C., Gebhart R.J. Group Y meningococcal disease in United States Air Force recruits. Am J Med 1977, 62:661-666.
207. Jackson L.A., Wenger J.D. Laboratory-based surveillance for meningococcal disease in selected areas, United States, 1989-1991. MMWR CDC Surveill Summ 1993, 42:21-30.
208. Rosenstein N.E., Perkins B.A., Stephens D.S., et al. The changing epidemiology of meningococcal disease in the United States, 1992-1996. J Infect Dis 1999, 180:1894-1901.
209. Harrison L.H. Epidemiological profile of meningococcal disease in the United States. Clin Infect Dis 2010, 50(Suppl. 2):S37-S44.
210. Ines Agudelo C., Sanabria O.M., Ovalle M.V. Serogroup Y meningococcal disease, Colombia. Emerg Infect Dis 2008, 14:990-991.
211. Le Saux N., Bettinger J.A., Wootton S., et al. Profile of serogroup Y meningococcal infections in Canada: implications for vaccine selection. Can J Infect Dis Med Microbiol 2009, 20:e130-e134.
212. Coulson G.B., von Gottberg A., du Plessis M., et al. Meningococcal disease in South Africa, 1999-2002. Emerg Infect Dis 2007, 13:273-281.
213. Hedberg S.T., Törös B., Fredlund H., et al. Genetic characterisation of the emerging invasive Neisseria meningitidis serogroup Y in Sweden, 2000 to 2010. Euro Surveill 2011, 16. http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19885.
214. Broker M. Increase of meningococcal serogroup Y cases in Europe. A reason for concern? Hum Vaccin Immunother 2012, 8. epub:2012/04/18.
215. Bidmos F.A., Neal K.R., Oldfield N.J., et al. Persistence, replacement, and rapid clonal expansion of meningococcal carriage isolates in a 2008 university student cohort. J Clin Microbiol 2011, 49:506-512.
216. Yazdankhah S.P., Kriz P., Tzanakaki G., et al. Distribution of serogroups and genotypes among disease-associated and carried isolates of Neisseria meningitidis from the Czech Republic, Greece, and Norway. J Clin Microbiol 2004, 42:5146-5153.
217. Glitza I.C., Ehrhard I., Muller-Pebody B., et al. Longitudinal study of meningococcal carrier rates in teenagers. Int J Hyg Environ Health 2008, 211:263-272.
218. Popovic T., Sacchi C.T., Reeves M.W., et al. Neisseria meningitidis serogroup W135 isolates associated with the ET-37 complex. Emerg Infect Dis 2000, 6:428-429.
219. Taha M.K., Achtman M., Alonso J.M., et al. Serogroup W135 meningococcal disease in Hajj pilgrims. Lancet 2000, 356:2159.
220. Taha M.K., Giorgini D., Ducos-Galand M., et al. Continuing diversification of Neisseria meningitidis W135 as a primary cause of meningococcal disease after emergence of the serogroup in 2000. J Clin Microbiol 2004, 42:4158-4163.
221. Mayer L.W., Reeves M.W., Al-Hamdan N., et al. Outbreak of W135 meningococcal disease in 2000: not emergence of a new W135 strain but clonal expansion within the electophoretic type-37 complex. J Infect Dis 2002, 185:1596-1605.
222. Kwara A., Adegbola R.A., Corrah P.T., et al. Meningitis caused by a serogroup W135 clone of the ET-37 complex of Neisseria meningitidis in West Africa. Trop Med Int Health 1998, 3:742-746.
223. Hahne S., Handford S., Ramsay M. W135 meningococcal carriage in Hajj pilgrims. Lancet 2002, 360:2089-2090.
224. Hahne S.J., Gray S.J., Jean F., et al. W135 meningococcal disease in England and Wales associated with Hajj 2000 and 2001. Lancet 2002, 359:582-583.
225. Dull P.M., Abdelwahab J., Sacchi C.T., et al. Neisseria meningitidis serogroup W-135 carriage among US travelers to the 2001 Hajj. J Infect Dis 2005, 191:33-39.
226. Meningococcal disease, serogroup W135, Burkina Faso. Preliminary report, 2002. Wkly Epidemiol Rec 2002, 77:152-155.
227. Decosas J., Koama J.B. Chronicle of an outbreak foretold: meningococcal meningitis W135 in Burkina Faso. Lancet Infect Dis 2002, 2:763-765.
228. Doyle T.J., Mejia-Echeverry A., Fiorella P., et al. Cluster of serogroup W135 meningococci, southeastern Florida, 2008-2009. Emerg Infect Dis 2010, 16:113-115.
229. Efron A.M., Sorhouet C., Salcedo C., et al. Significant increase of serogroup W135 invasive Neisseria meningitidis strains in Argentina: a new epidemiological feature of the region 2008.
230. Weidlich L., Baethgen L.F., Mayer L.W., et al. High prevalence of Neisseria meningitidis hypervirulent lineages and emergence of W135:P1.5,2:ST-11 clone in Southern Brazil. J Infect 2008, 57:324-331.
231. Efron A.M., Sorhouet C., Salcedo C., et al. W135 invasive meningococcal strains spreading in South America: significant increase in incidence rate in Argentina. J Clin Microbiol 2009, 47:1979-1980.
232. Granoff D.M. Relative importance of complement-mediated bactericidal and opsonic activity for protection against meningococcal disease. Vaccine 2009, 27(Suppl. 2):B117-B125.
233. Trotter C.L., Gay N.J., Edmunds W.J. The natural history of meningococcal carriage and disease. Epidemiol Infect 2006, 134:556-566.
234. Goldschneider I., Gotschlich E.C., Artenstein M.S. Human immunity to the meningococcus, II: development of natural immunity. J Exp Med 1969, 129:1327-1348.
235. Trotter C., Findlow J., Balmer P., et al. Seroprevalence of bactericidal and anti-outer membrane vesicle antibodies to Neisseria meningitidis group B in England. Clin Vaccine Immunol 2007, 14:863-868.
236. Gorringe A.R. Can Neisseria lactamica antigens provide an effective vaccine to prevent meningococcal disease?. Expert Rev Vaccines 2005, 4:373-379.
237. Oliver K.J., Reddin K.M., Bracegirdle P., et al. Neisseria lactamica protects against experimental meningococcal infection. Infect Immun 2002, 70:3621-3626.
238. Blakebrough I.S., Greenwood B.M., Whittle H.C., et al. The epidemiology of infections due to Neisseria meningitidis and Neisseria lactamica in a northern Nigerian community. J Infect Dis 1982, 146:626-637.
239. Vann W.F., Liu T.Y., Robbins J.B. Bacillus pumilus polysaccharide cross-reactive with meningococcal group A polysaccharide. Infect Immun 1976, 13:1654-1662.
240. Myerowitz R.L., Gordon R.E., Robbins J.B. Polysaccharides of the genus Bacillus cross-reactive with the capsular polysaccharides of Diplococcus pneumoniae type 3, Haemophilus influenzae type b, and Neisseria meningitidis group A. Infect Immun 1973, 8:896-900.
241. Robbins J.B., Myerowitz L., Whisnant J.K., et al. Enteric bacteria cross-reactive with Neisseria meningitidis groups A and C and Diplococcus pneumoniae types I and 3. Infect Immun 1972, 6:651-656.
242. Platonov A.E., Beloborodov V.B., Gabrilovitch D.I., et al. Immunological evaluation of late complement component-deficient individuals. Clin Immunol Immunopathol 1992, 64:98-105.
243. Platonov A.E., Beloborodov V.B., Vershinina I.V. Meningococcal disease in patients with late complement component deficiency: studies in the U.S.S.R. Medicine (Baltimore) 1993, 72:374-392.
244. Figueroa J., Andreoni J., Densen P. Complement deficiency states and meningococcal disease. Immunol Res 1993, 12:295-311.
245. Figueroa J.E., Densen P. Infectious diseases associated with complement deficiencies. Clin Microbiol Rev 1991, 4:359-395.
246. Fijen C.A., Kuijper E.J., Hannema A.J., et al. Complement deficiencies in patients over ten years old with meningococcal disease due to uncommon serogroups. Lancet 1989, 2:585-588.
247. de Paula P.F., Barbosa J.E., Junior P.R., et al. Ontogeny of complement regulatory proteins: concentrations of factor H, factor I, c4b-binding protein, properdin and vitronectin in healthy children of different ages and in adults. Scand J Immunol 2003, 58:572-577.
248. Welsch J.A., Granoff D. Naturally acquired passive protective activity against Neisseria meningitidis group C in the absence of serum bactericidal activity. Infect Immun 2004, 72:5903-5909.
249. Granoff D.M., Morgan A., Welsch J.A. Immunogenicity of an investigational quadrivalent Neisseria meningitidis-diphtheria toxoid conjugate vaccine in 2-year old children. Vaccine 2005, 23:4307-4314.
250. Amir J., Louie L., Granoff D.M. Naturally-acquired immunity to Neisseria meningitidis group A. Vaccine 2005, 23:977-983.
251. Mitchell L.A., Ochnio J.J., Glover C., et al. Analysis of meningococcal serogroup C-specific antibody levels in British Columbian children and adolescents. J Infect Dis 1996, 173:1009-1013.
252. Trotter C., Borrow R., Andrews N. Seroprevalence of meningococcal serogroup C bactericidal antibody in England and Wales in the pre-vaccination era. Vaccine 2003, 21:1094-1098.
253. Platonov A.E., Vershinina I.V., Kayhty H., et al. Antibody-dependent killing of meningococci by human neutrophils in serum of late complement component-deficient patients. Int Arch Allergy Immunol 2003, 130:314-321.
254. Platonov A.E., Vershinina I.V., Kuijper E.J., et al. Long term effects of vaccination of patients deficient in a late complement component with a tetravalent meningococcal polysaccharide vaccine. Vaccine 2003, 21:4437-4447.
255. Granoff D.M., Harris S.L. Protective activity of group C anticapsular antibodies elicited in two-year-olds by an investigational quadrivalent Neisseria meningitidis-diphtheria toxoid conjugate vaccine. Pediatr Infect Dis J 2004, 23:490-497.
256. Harris S.L., King W.J., Ferris W., et al. Age-related disparity in functional activities of human group C serum anticapsular antibodies elicited by meningococcal polysaccharide vaccine. Infect Immun 2003, 71:275-286.
257. Vu D.M., Kelly D., Heath P.T., et al. Effectiveness analyses may underestimate protection of infants after group C meningococcal immunization. J Infect Dis 2006, 194:231-237.
258. Vu D.M., Welsch J.A., Zuno-Mitchell P., et al. Antibody persistence 3 years after immunization of adolescents with quadrivalent meningococcal conjugate vaccine. J Infect Dis 2006, 193:821-828.
259. Toropainen M., Saarinen L., van der Ley P., et al. Murine monoclonal antibodies to PorA of Neisseria meningitidis show reduced protective activity in against B:15:P1.7,16 subtype variants in an infant rat infection model. Microb Pathog 2001, 30:139-148.
260. Toropainen M., Saarinen L., Wedege E., et al. Passive protection in the infant rat protection assay by sera taken before and after vaccination of teenagers with serogroup B meningococcal outer membrane vesicle vaccines. Vaccine 2005, 23:4821-4833.
261. Toropainen M., Saarinen L., Wedege E., et al. Protection by natural human immunoglobulin M antibody to meningococcal serogroup B capsular polysaccharide in the infant rat protection assay is independent of complement-mediated bacterial lysis. Infect Immun 2005, 73:4694-4703.
262. Toropainen M., Saarinen L., Vidarsson G., et al. Protection by meningococcal outer membrane protein PorA-specific antibodies and a serogroup B capsular polysaccharide-specific antibody in complement-sufficient and C6-deficient infant rats. Infect Immun 2006, 74:2803-2808.
263. Masignani V., Comanducci M., Giuliani M.M., et al. Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870. J Exp Med 2003, 197:789-799.
264. Welsch J.A., Moe G.R., Rossi R., et al. Antibody to genome-derived neisserial antigen 2132, a Neisseria meningitidis candidate vaccine, confers protection against bacteremia in the absence of complement-mediated bactericidal activity. J Infect Dis 2003, 188:1730-1740.
265. Welsch J.A., Rossi R., Comanducci M., et al. Protective activity of monoclonal antibodies to genome-derived neisserial antigen 1870, a Neisseria meningitidis candidate vaccine. J Immunol 2004, 172:5606-5615.
266. Gheesling L.L., Carlone G.M., Pais L.B., et al. Multicenter comparison of Neisseria meningitidis serogroup C anti-capsular polysaccharide antibody levels measured by a standardized enzyme-linked immunosorbent assay. J Clin Microbiol 1994, 32:1475-1482.
267. Harris S.L., Finn A., Granoff D.M. Disparity in functional activity between serum anticapsular antibodies induced in adults by immunization with an investigational group A and C Neisseria meningitidis-diphtheria toxoid conjugate vaccine and by a polysaccharide vaccine. Infect Immun 2003, 71:3402-3408.
268. Peltola H., Makela H., Kayhty H., et al. Clinical efficacy of meningococcus group A capsular polysaccharide vaccine in children three months to five years of age. N Engl J Med 1977, 297:686-691.
269. Granoff D.M., Maslanka S.E., Carlone G.M., et al. A modified enzyme-linked immunosorbent assay for measurement of antibody responses to meningococcal C polysaccharide that correlate with bactericidal responses. Clin Diagn Lab Immunol 1998, 5:479-485.
270. Maslanka S.E., Gheesling L.L., Libutti D.E., et al. Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. The Multilaboratory Study Group. Clin Diagn Lab Immunol 1997, 4:156-167.
271. Granoff D.M., Morgan A., Welsch J.A. Persistence of group C anticapsular antibodies two to three years after immunization with an investigational quadrivalent Neisseria meningitidis-diphtheria toxoid conjugate vaccine. Pediatr Infect Dis J 2005, 24:132-136.
272. Borrow R., Andrews N., Goldblatt D., et al. Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection. Infect Immun 2001, 69:1568-1573.
273. Santos G.F., Deck R.R., Donnelly J., et al. Importance of complement source in measuring meningococcal bactericidal titers. Clin Diagn Lab Immunol 2001, 8:616-623.
274. Granoff D.M., Welsch J.A., Ram S. Binding of complement factor H (fH) to Neisseria meningitidis is specific for human fH and inhibits complement activation by rat and rabbit sera. Infect Immun 2009, 77:764-769.
275. Borrow R., Carlone G.M., Rosenstein N., et al. Neisseria meningitidis group B correlates of protection and assay standardization: international meeting report Emory University, Atlanta, Georgia, United States, 16-17 March 2005. Vaccine 2006, 24:5093-5107.
276. Borrow R., Balmer P., Miller E. Meningococcal surrogates of protection: serum bactericidal antibody activity. Vaccine 2005, 23:2222-2227.
277. Andrews N., Borrow R., Miller E. Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England. Clin Diagn Lab Immunol 2003, 10:780-786.
278. Pollard A.J., Perrett K.P., Beverley P.C. Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines. Nat Rev Immunol 2009, 9:213-220.
279. Granoff D.M., Pollard A.J. Reconsideration of the use of meningococcal polysaccharide vaccine. Pediatr Infect Dis J 2007, 26:716-722.
280. Granoff D.M., Gupta R.K., Belshe R.B., et al. Induction of immunologic refractoriness in adults by meningococcal C polysaccharide vaccination. J Infect Dis 1998, 178:870-874.
281. Trotter C.L., Andrews N.J., Kaczmarski E.B., et al. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet 2004, 364:365-367.
282. Edwards E.A., Devine L.F., Sengbusch G.H., et al. Immunological investigations of meningococcal disease, III: brevity of group C acquisition prior to disease occurrence. Scand J Infect Dis 1977, 9:105-110.
283. Snape M.D., Kelly D.F., Salt P., et al. Serogroup C meningococcal glycoconjugate vaccine in adolescents: persistence of bactericidal antibodies and kinetics of the immune response to a booster vaccine more than 3 years after immunization. Clin Infect Dis 2006, 43:1387-1394.
284. MacLennan J., Obaro S., Deeks J., et al. Immunologic memory 5 years after meningococcal A/C conjugate vaccination in infancy. J Infect Dis 2001, 183:97-104.
285. Goldblatt D., Vaz A.R., Miller E. Antibody avidity as a surrogate marker of successful priming by Haemophilus influenzae type b conjugate vaccines following infant immunization. J Infect Dis 1998, 177:1112-1115.
286. Borrow R., Goldblatt D., Andrews N., et al. Antibody persistence and immunological memory at age 4 years after meningococcal group C conjugate vaccination in children in the United Kingdom. J Infect Dis 2002, 186:1353-1357.
287. Goldblatt D., Borrow R., Miller E. Natural and vaccine-induced immunity and immunologic memory to Neisseria meningitidis serogroup C in young adults. J Infect Dis 2002, 185:397-400.
288. Snape M.D., Maclennan J.M., Lockhart S., et al. Demonstration of immunologic memory using serogroup C meningococcal glycoconjugate vaccine. Pediatr Infect Dis J 2009, 28:92-97.
289. Kelly D.F., Snape M.D., Clutterbuck E.A., et al. CRM197-conjugated serogroup C meningococcal capsular polysaccharide, but not the native polysaccharide, induces persistent antigen specific memory B cells. Blood 2006, 108:2642-2647.
290. Blanchard Rohner G., Snape M.D., Kelly D.F., et al. The magnitude of the antibody and memory B cell responses during priming with a protein-polysaccharide conjugate vaccine in human infants is associated with the persistence of antibody and the intensity of booster response. J Immunol 2008, 180:2165-2173.
291. Marsh J.W., O'Leary M.M., Shutt K.A., et al. Deletion of fetA gene sequences in serogroup B and C Neisseria meningitidis isolates. J Clin Microbiol 2007, 45:1333-1335.
292. Lucidarme J., Tan L., Exley R.M., et al. Characterisation of Neisseria meningitidis isolates that do not express the virulence factor and vaccine antigen, factor H binding protein. Clin Vaccine Immunol 2011, 18:1002-1014.
293. Saunders N.J., Jeffries A.C., Peden J.F., et al. Repeat-associated phase variable genes in the complete genome sequence of Neisseria meningitidis strain MC58. Mol Microbiol 2000, 37:207-215.
294. Feavers I.M. ABC of meningococcal diversity. Nature 2000, 404:451-452.
295. Sophian A., Black J. Prophylactic vaccination against epidemic meningitis. JAMA 1912, 59:527-532.
296. Greenwood M. The outbreak of cerebrospinal fever at Salisbury in 1914-15. Proc R Soc Med 1916, 10:44-60.
297. Gates F.L. A report on antimeningitis vaccination and observations on agglutinins in the blood of chronic meningococcus carriers. J Exp Med 1918, 28:449-474.
298. Underwood E.A. Recent knowledge of the incidence and control of cerebrospinal fever. Br Med J 1940, i:757-763.
299. Ferry N.S., Steele A.H. Active immunization with meningococcus toxin. JAMA 1935, 104:983-984.
300. Kuhns D., Kisner P., Williams M.P., et al. The control of meningococcic meningitis epidemics by active immunization with meningococcus soluble toxin: further studies. JAMA 1938, 110:484-487.
301. Miller J.W., Siess E.E., Feldman H.A. In and in resistance to sulfadiazine in strains of Neisseria meningitidis. JAMA 1963, 186:139-141.
302. Scherp H.W., Rake G. Studies on meningococcal infection, XIII: correlation between antipolysaccharide and the antibody which protects mice against infection with type I meningococci. J Exp Med 1944, 81:85-92.
303. Kabat E.A., Kaiser H., Sikorski H. Preparation of the type specific polysaccharide of the type I meningococcus and a study of its effectiveness as an antigen in human beings. J Exp Med 1944, 80:229-307.
304. Watson R.G., Scherp H.W. The specific hapten of serogroup C (group II alpha) meningococcus, I: preparation and immunological behaviour. J Immunol 1958, 81:331-336.
305. Kabat E.A., Bezer A.E. The effect of variation on molecular weight on the antigenicity of dextran in man. Arch Biochem 1958, 78:306-313.
306. Gotschlich E.C., Rey M., Triau R., et al. Quantitative determination of the human immune response to immunization with meningococcal vaccines. J Clin Invest 1972, 51:89-96.
307. Gotschlich E.C., Liu T.Y., Artenstein M.S. Human immunity to the meningococcus, 3: preparation and immunochemical properties of the group A, group B, and group C meningococcal polysaccharides. J Exp Med 1969, 129:1349-1365.
308. Gotschlich E.C., Goldschneider I., Artenstein M.S. Human immunity to the meningococcus, IV: immunogenicity of group A and group C meningococcal polysaccharides in human volunteers. J Exp Med 1969, 129:1367-1384.
309. Leach A., Twumasi P.A., Kumah S., et al. Induction of immunologic memory in Gambian children by vaccination in infancy with a group A plus group C meningococcal polysaccharide-protein conjugate vaccine. J Infect Dis 1997, 175:200-204.
310. Goldblatt D. Immunisation and the maturation of infant immune responses. Dev Biol Stand 1998, 95:125-132.
311. Robbins J.B., Schneerson R., Anderson P., et al. The 1996 Albert Lasker Medical Research Awards: prevention of systemic infections, especially meningitis, caused by Haemophilus influenzae type b: impact on public health and implications for other polysaccharide-based vaccines. JAMA 1996, 276:1181-1185.
312. Anderson P., Pichichero M.E., Insel R.A. Immunization of 2-month-old infants with protein-coupled oligosaccharides derived from the capsule of Haemophilus influenzae type b. J Pediatr 1985, 107:346-351.
313. Granoff D.M., Boies E.G., Munson R.S. Immunogenicity of Haemophilus influenzae type b polysaccharide-diphtheria toxoid conjugate vaccine in adults. J Pediatr 1984, 105:22-27.
314. Einhorn M.S., Weinberg G.A., Anderson E.L., et al. Immunogenicity in infants of Haemophilus influenzae type B polysaccharide in a conjugate vaccine with Neisseria meningitidis outer-membrane protein. Lancet 1986, 2:299-302.
315. Costantino P., Viti S., Podda A., et al. Development and phase 1 clinical testing of a conjugate vaccine against meningococcus A and C. Vaccine 1992, 10:691-698.
316. MacDonald N.E., Halperin S.A., Law B.J., et al. Induction of immunologic memory by conjugated vs plain meningococcal C polysaccharide vaccine in toddlers: a randomized controlled trial. JAMA 1998, 280:1685-1689.
317. Richmond P., Borrow R., Miller E., et al. Meningococcal serogroup C conjugate vaccine is immunogenic in infancy and primes for memory. J Infect Dis 1999, 179:1569-1572.
318. Richmond P., Goldblatt D., Fusco P.C., et al. Safety and immunogenicity of a new Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine in healthy adults. Vaccine 1999, 18:641-646.
319. MacLennan J.M., Shackley F., Heath P.T., et al. Safety, immunogenicity, and induction of immunologic memory by a serogroup C meningococcal conjugate vaccine in infants: a randomized controlled trial. JAMA 2000, 283:2795-2801.
320. Campbell J.D., Edelman R., King J.C., et al. Safety, reactogenicity, and immunogenicity of a tetravalent meningococcal polysaccharide-diphtheria toxoid conjugate vaccine given to healthy adults. J Infect Dis 2002, 186:1848-1851.
321. Pichichero M., Casey J., Blatter M., et al. Comparative trial of the safety and immunogenicity of quadrivalent (A, C, Y, W-135) meningococcal polysaccharide-diphtheria conjugate vaccine versus quadrivalent polysaccharide vaccine in two- to ten-year-old children. Pediatr Infect Dis J 2005, 24:57-62.
322. Keyserling H., Papa T., Koranyi K., et al. Safety, immunogenicity, and immune memory of a novel meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine (MCV-4) in healthy adolescents. Arch Pediatr Adolesc Med 2005, 159:907-913.
323. Granoff D.M. Review of meningococcal group B vaccines. Clin Infect Dis 2010, 50(Suppl. 2):S54-S65.
324. Sadarangani M., Pollard A.J. Serogroup B meningococcal vaccines: an unfinished story. Lancet Infect Dis 2010, 10:112-124.
325. Trotter C.L., Ramsay M.E., Slack M.P. Rising incidence of Haemophilus influenzae type b disease in England and Wales indicates a need for a second catch-up vaccination campaign. Commun Dis Public Health 2003, 6:55-58.
326. Zhou J., Lottenbach K.R., Barenkamp S.J., et al. Recurrent variable region gene usage and somatic mutation in the human antibody response to the capsular polysaccharide of Streptococcus pneumoniae type 23F. Infect Immun 2002, 70:4083-4091.
327. Barington T., Hougs L., Juul L., et al. The progeny of a single virgin B cell predominates the human recall B cell response to the capsular polysaccharide of Haemophilus influenzae type b. J Immunol 1996, 157:4016-4027.
328. Baxendale H.E., Davis Z., White H.N., et al. Immunogenetic analysis of the immune response to pneumococcal polysaccharide. Eur J Immunol 2000, 30:1214-1223.
329. Zangwill K.M., Stout R.W., Carlone G.M., et al. Duration of antibody response after meningococcal polysaccharide vaccination in US Air Force personnel. J Infect Dis 1994, 169:847-852.
330. Campagne G., Garba A., Fabre P., et al. Safety and immunogenicity of three doses of a Neisseria meningitidis A + C diphtheria conjugate vaccine in infants from Niger. Pediatr Infect Dis J 2000, 19:144-150.
331. Lieberman J.M., Chiu S.S., Wong V.K., et al. Safety and immunogenicity of a serogroups A/C Neisseria meningitidis oligosaccharide-protein conjugate vaccine in young children: a randomized controlled trial. JAMA 1996, 275:1499-1503.
332. Maslanka S.E., Tappero J.W., Plikaytis B.D., et al. Age-dependent Neisseria meningitidis serogroup C class-specific antibody concentrations and bactericidal titers in sera from young children from Montana immunized with a licensed polysaccharide vaccine. Infect Immun 1998, 66:2453-2459.
333. Granoff D.M. Assessing efficacy of Haemophilus influenzae type b combination vaccines. Clin Infect Dis 2001, 33(Suppl. 4):S278-S287.
334. Jodar L., Cartwright K., Feavers I.M. Standardisation and validation of serological assays for the evaluation of immune responses to Neisseria meningitidis serogroup A and C vaccines. Biologicals 2000, 28:193-197.
335. Gold R., Lepow M.L., Goldschneider I., et al. Kinetics of antibody production to group A and group C meningococcal polysaccharide vaccines administered during the first six years of life: prospects for routine immunization of infants and children. J Infect Dis 1979, 140:690-697.
336. Jokhdar H., Borrow R., Sultan A., et al. Immunologic hyporesponsiveness to serogroup C but not serogroup A following repeated meningococcal A/C polysaccharide vaccination in Saudi Arabia. Clin Diagn Lab Immunol 2004, 11:83-88.
337. Vu D.M., de Boer A.W., Danzig L., et al. Priming for immunologic memory in adults by meningococcal group C conjugate vaccination. Clin Vaccine Immunol 2006, 13:605-610.
338. De Wals P., De Serres G., Niyonsenga T. Effectiveness of a mass immunization campaign against serogroup C meningococcal disease in Quebec. JAMA 2001, 285:177-181.
339. Rosenstein N., Levine O., Taylor J.P., et al. Efficacy of meningococcal vaccine and barriers to vaccination. JAMA 1998, 279:435-439.
340. Jackson L.A., Schuchat A., Reeves M.W., et al. Serogroup C meningococcal outbreaks in the United States: an emerging threat. JAMA 1995, 273:383-389.
341. Artenstein M.S., Gold R., Zimmerly J.G., et al. Prevention of meningococcal disease by group C polysaccharide vaccine. N Engl J Med 1970, 282:417-420.
342. Gold R., Artenstein M.S. Meningococcal infections, 2: field trial of group C meningococcal polysaccharide vaccine in 1969-70. Bull World Health Organ 1971, 45:279-282.
343. Gardner P. Clinical practice: prevention of meningococcal disease. N Engl J Med 2006, 355:1466-1473.
344. Brundage J.F., Ryan M.A., Feighner B.H., et al. Meningococcal disease among United States military service members in relation to routine uses of vaccines with different serogroup-specific components, 1964-1998. Clin Infect Dis 2002, 35:1376-1381.
345. Keiser P.B., Hamilton L., Broderick M. U.S. military fatalities due to Neisseria meningitidis: case reports and historical perspective. Mil Med 2011, 176:308-311.
346. Taunay A.E., Feldman R.A., Bastos C.O., et al. Avaliacao do efeito protector de vacina polissacaridica antimeningococica do groupo C, em criancas de 6 A 36 meses. Rev Inst Adolfo Lutz 1978, 38:77-82.
347. Espin Rios I., Garcia-Fulgueiras A., Navarro Alonso J.A., et al. Seroconversion and duration of immunity after vaccination against group C meningococcal infection in young children. Vaccine 2000, 18:2656-2660.
348. Flitter B.A., Ismail A., Vu D., et al. Group A antibody persistence five years after meningococcal polysaccharide vaccination in the Sudan. Hum Vaccin 2007, 3:135-138.
349. Greenwood B.M., Hassan-King M., Whittle H.C. Prevention of secondary cases of meningococcal disease in household contacts by vaccination. Br Med J 1978, 1:1317-1319.
350. Saliou P., Stoeckel P., Lafaye A., et al. Controlled tests of anti-meningococcal polysaccharide A vaccine in the African Sahel area (Upper Volta and Mali) [in French]. Dev Biol Stand 1978, 41:97-108.
351. Erwa H.H., Haseeb M.A., Idris A.A., et al. A serogroup A meningococcal polysaccharide vaccine: studies in the Sudan to combat cerebrospinal meningitis caused by Neisseria meningitidis group A. Bull World Health Organ 1973, 49:301-305.
352. Wahdan M.H., Sallam S.A., Hassan M.N., et al. A second controlled field trial of a serogroup A meningococcal polysaccharide vaccine in Alexandria. Bull World Health Organ 1977, 55:645-651.
353. Wahdan M.H., Rizk F., el-Akkad A.M., et al. A controlled field trial of a serogroup A meningococcal polysaccharide vaccine. Bull World Health Organ 1973, 48:667-673.
354. Reingold A.L., Broome C.V., Hightower A.W., et al. Age-specific differences in duration of clinical protection after vaccination with meningococcal polysaccharide A vaccine. Lancet 1985, 2:114-118.
355. Ismail A.A., Harris S.L., Granoff D.M. Serum group a anticapsular antibodies in a Sudanese population immunized with meningococcal polysaccharide vaccine during a group A epidemic. Pediatr Infect Dis J 2004, 23:748-755.
356. MacLennan J., Obaro S., Deeks J., et al. Immune response to revaccination with meningococcal A and C polysaccharides in Gambian children following repeated immunisation during early childhood. Vaccine 1999, 17:3086-3093.
357. World Health Organization Requirements for meningococcal polysaccharide vaccine 1980, World Health Organization, Geneva, Switzerland, World Health Organization Technical Report Series No. 23.
358. Devine L.F., Pierce W.E., Floyd T.M., et al. Evaluation of group C meningococcal polysaccharide vaccine in marine recruits, San Diego, California. Am J Epidemiol 1970, 92:25-32.
359. Stroffolini T., Angelini L., Galanti I., et al. The effect of meningococcal group A and C polysaccharide vaccine on nasopharyngeal carrier state. Microbiologica 1990, 13:225-229.
360. Di Martino M., Cali G., Astorre P., et al. Meningococcal carriage and vaccination in army recruits in Italy. Boll Ist Sieroter Milan 1990, 69:357-359.
361. Sivonen A. Effect of Neisseria meningitidis group A polysaccharide vaccine on nasopharyngeal carrier rates. J Infect 1981, 3:266-272.
362. Blakebrough I.S., Greenwood B.M., Whittle H.C., et al. Failure of meningococcal vaccination to stop the transmission of meningococci in Nigerian schoolboys. Ann Trop Med Parasitol 1983, 77:175-178.
363. Hassan-King M.K., Wall R.A., Greenwood B.M. Meningococcal carriage, meningococcal disease and vaccination. J Infect 1988, 16:55-59.
364. Schwartz B., Al-Tobaiqi A., Al-Ruwais A., et al. Comparative efficacy of ceftriaxone and rifampicin in eradicating pharyngeal carriage of group A Neisseria meningitidis. Lancet 1988, 1. 1239-142.
365. Michon F., Huang C.H., Farley E.K., et al. Structure activity studies on group C meningococcal polysaccharide-protein conjugate vaccines: effect of O-acetylation on the nature of the protective epitope. Dev Biol (Basel) 2000, 103:151-160.
366. Ho M.M., Bolgiano B., Corbel M.J. Assessment of the stability and immunogenicity of meningococcal oligosaccharide C-CRM197 conjugate vaccines. Vaccine 2000, 19:716-725.
367. Ho M.M., Lemercinier X., Bolgiano B., et al. Monitoring stability of meningococcal group C conjugate vaccines; correlation of physico-chemical methods and immunogenicity assays. Dev Biol (Basel) 2000, 103:139-150.
368. Richmond P., Borrow R., Findlow J., et al. Evaluation of De-O-acetylated meningococcal C polysaccharide-tetanus toxoid conjugate vaccine in infancy: reactogenicity, immunogenicity, immunologic priming, and bactericidal activity against O-acetylated and De-O-acetylated serogroup C strains. Infect Immun 2001, 69:2378-2382.
369. Richmond P., Borrow R., Goldblatt D., et al. Ability of 3 different meningococcal C conjugate vaccines to induce immunologic memory after a single dose in UK toddlers. J Infect Dis 2001, 183:160-163.
370. Kelly D.F., Pollard A.J., Moxon E.R. Immunological memory: the role of B cells in long-term protection against invasive bacterial pathogens. JAMA 2005, 294:3019-3023.
371. Joseph H., Miller E., Dawson M., et al. Meningococcal serogroup a avidity indices as a surrogate marker of priming for the induction of immunologic memory after vaccination with a meningococcal A/C conjugate vaccine in infants in the United Kingdom. J Infect Dis 2001, 184:661-662.
372. Borrow R., Goldblatt D., Finn A., et al. Immunogenicity of, and immunologic memory to, a reduced primary schedule of meningococcal C-tetanus toxoid conjugate vaccine in infants in the United kingdom. Infect Immun 2003, 71:5549-5555.
373. Southern J., Crowley-Luke A., Borrow R., et al. Immunogenicity of one, two or three doses of a meningococcal C conjugate vaccine conjugated to tetanus toxoid, given as a three-dose primary vaccination course in UK infants at 2, 3 and 4 months of age with acellular pertussis-containing DTP/Hib vaccine. Vaccine 2006, 24:215-219.
374. Southern J., Borrow R., Andrews N., et al. Immunogenicity of a reduced schedule of meningococcal group C conjugate vaccine given concomitantly with the Prevenar and Pediacel vaccines in healthy infants in the United Kingdom. Clin Vaccine Immunol 2009, 16:194-199.
375. Kitchin N.R., Southern J., Morris R., et al. Evaluation of a diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae type b vaccine given concurrently with meningococcal group C conjugate vaccine at 2, 3 and 4 months of age. Arch Dis Child 2007, 92:11-16.
376. Barington T., Skettrup M., Juul L., et al. Non-epitope-specific suppression of the antibody response to Haemophilus influenzae type b conjugate vaccines by preimmunization with vaccine components. Infect Immun 1993, 61:432-438.
377. Peeters C.C., Tenbergen-Meekes A.M., Poolman J.T., et al. Effect of carrier priming on immunogenicity of saccharide-protein conjugate vaccines. Infect Immun 1991, 59:3504-3510.
378. Di John D., Wasserman S.S., Torres J.R., et al. Effect of priming with carrier on response to conjugate vaccine. Lancet 1989, 2:1415-1418.
379. Goldblatt D., Southern J., Ashton L., et al. Immunogenicity and boosting after a reduced number of doses of a pneumococcal conjugate vaccine in infants and toddlers. Pediatr Infect Dis J 2006, 25:312-319.
380. Buttery J.P., Riddell A., McVernon J., et al. Immunogenicity and safety of a combination pneumococcal-meningococcal vaccine in infants: a randomized controlled trial. JAMA 2005, 293:1751-1758.
381. Southern J., Deane S., Ashton L., et al. Effects of prior polysaccharide vaccination on magnitude, duration, and quality of immune responses to and safety profile of a meningococcal serogroup C tetanus toxoid conjugate vaccination in adults. Clin Diagn Lab Immunol 2004, 11:1100-1104.
382. Choo S., Zuckerman J., Goilav C., et al. Immunogenicity and reactogenicity of a group C meningococcal conjugate vaccine compared with a group A+C meningococcal polysaccharide vaccine in adolescents in a randomised observer-blind controlled trial. Vaccine 2000, 18:2686-2692.
383. Snape M.D., Kelly D.F., Lewis S., et al. Seroprotection against serogroup C meningococcal disease in adolescents in the United Kingdom: observational study. BMJ 2008, 336:1487-1491.
384. Perrett K.P., Winter A.P., Kibwana E., et al. Antibody persistence after serogroup C meningococcal conjugate immunization of United Kingdom primary-school children in 1999-2000 and response to a booster: a phase 4 clinical trial. Clin Infect Dis 2010, 50:1601-1610.
385. Borrow R., Andrews N., Findlow H., et al. Kinetics of antibody persistence following administration of a combination meningococcal serogroup C and Haemophilus influenzae type b conjugate vaccine in healthy infants in the United Kingdom primed with a monovalent meningococcal serogroup C vaccine. Clin Vaccine Immunol 2010, 17:154-159.
386. Khatami A., Snape M.D., Davis E., et al. Persistence of the immune response at 5 years of age following infant immunisation with investigational quadrivalent MenACWY conjugate vaccine formulations. Vaccine 2012, 30:2831-2838.
387. Borrow R., Southern J., Andrews N., et al. Comparison of antibody kinetics following meningococcal serogroup C conjugate vaccine between healthy adults previously vaccinated with meningococcal A/C polysaccharide vaccine and vaccine-naive controls. Vaccine 2001, 19:3043-3050.
388. MacDonald N.E., Halperin S.A., Law B.J., et al. Can meningococcal C conjugate vaccine overcome immune hyporesponsiveness induced by previous administration of plain polysaccharide vaccine?. JAMA 2000, 283:1826-1827.
389. Davison K.L., Ramsay M.E., Crowcroft N.S., et al. Estimating the burden of serogroup C meningococcal disease in England and Wales. Commun Dis Public Health 2002, 5:213-219.
390. Miller E., Salisbury D., Ramsay M. Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story. Vaccine 2001, 20(Suppl. 1):S58-S67.
391. Trotter C.L., Ramsay M.E., Kaczmarski E.B. Meningococcal serogroup C conjugate vaccination in England and Wales: coverage and initial impact of the campaign. Commun Dis Public Health 2002, 5:220-225.
392. Auckland C., Gray S., Borrow R., et al. Clinical and immunologic risk factors for meningococcal C conjugate vaccine failure in the United Kingdom. J Infect Dis 2006, 194:1745-1752.
393. Ramsay M.E., Andrews N., Kaczmarski E.B., et al. Efficacy of meningococcal serogroup C conjugate vaccine in teenagers and toddlers in England. Lancet 2001, 357:195-196.
394. Campbell H., Andrews N., Borrow R., et al. Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity. Clin Vaccine Immunol 2010, 17:840-847.
395. Larrauri A., Cano R., Garcia M., et al. Impact and effectiveness of meningococcal C conjugate vaccine following its introduction in Spain. Vaccine 2005, 23:4097-4100.
396. de Greeff S.C., de Melker H.E., Spanjaard L., et al. Protection from routine vaccination at the age of 14 months with meningococcal serogroup C conjugate vaccine in the Netherlands. Pediatr Infect Dis J 2006, 25:79-80.
397. De Wals P., Deceuninck G., Lefebvre B., et al. Effectiveness of serogroup C meningococcal conjugate vaccine: a 7-year follow-up in Quebec, Canada. Pediatr Infect Dis J 2011, 30:566-569.
398. Maiden M.C., Stuart J.M. Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination. Lancet 2002, 359:1829-1831.
399. Ramsay M.E., Andrews N.J., Trotter C.L., et al. Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis. BMJ 2003, 326:365-366.
400. Trotter C.L., Borrow R., Findlow J., et al. Seroprevalence of antibodies against serogroup C meningococci in England in the postvaccination era. Clin Vaccine Immunol 2008, 15:1694-1698.
401. Maiden M.C., Spratt B.G. Meningococcal conjugate vaccines: new opportunities and new challenges. Lancet 1999, 354:615-616.
402. Swartley J.S., Marfin A.A., Edupuganti S., et al. Capsule switching of Neisseria meningitidis. Proc Natl Acad Sci U S A 1997, 94:271-276.
403. Lancellotti M., Guiyoule A., Ruckly C., et al. Conserved virulence of C to B capsule switched Neisseria meningitidis clinical isolates belonging to ET-37/ST-11 clonal complex. Microbes Infect 2006, 8:191-196.
404. Balmer P., Borrow R., Miller E. Impact of meningococcal C conjugate vaccine in the UK. J Med Microbiol 2002, 51:717-722.
405. Castilla J., Vazquez J.A., Salcedo C., et al. B:2a:P1.5 Meningococcal strains likely arisen from capsular switching event still spreading in Spain. J Clin Microbiol 2009, 47:463-465.
406. Southern J., Gelb D., Andrews N., et al. Reactogenicity of meningococcal C conjugate vaccines when administered at the same time as, or a month prior to or after, tetanus and diphtheria booster vaccinations. Hum Vaccin 2006, 2:237-242.
407. Bilukha O.O., Rosenstein N. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2005, 54(RR-7):1-21.
408. Report from the Advisory Committee on Immunization Practices (ACIP): decision not to recommend routine vaccination of all children aged 2-10 years with quadrivalent meningococcal conjugate vaccine (MCV4). MMWR Morb Mortal Wkly Rep 2008, 57:462-465.
409. Licensure of a meningococcal conjugate vaccine (Menveo) and guidance for use: Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Morb Mortal Wkly Rep 2010, 59:273.
410. Nolan T., Richmond P., Marshall H., et al. Immunogenicity and safety of an investigational combined Haemophilus influenzae type B-Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine. Pediatr Infect Dis J 2011, 30:190-196.
411. Marshall G.S., Marchant C.D., Blatter M., et al. Immune response and one-year antibody persistence after a fourth dose of a novel Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine (HibMenCY) at 12 to 15 months of age. Pediatr Infect Dis J 2010, 29:469-471.
412. Rennels M., King J., Ryall R., et al. Dosage escalation, safety and immunogenicity study of four dosages of a tetravalent meninogococcal polysaccharide diphtheria toxoid conjugate vaccine in infants. Pediatr Infect Dis J 2004, 23:429-435.
413. Rennels M., King J., Ryall R., et al. Dose escalation, safety and immunogenicity study of a tetravalent meninogococcal polysaccharide diphtheria conjugate vaccine in toddlers. Pediatr Infect Dis J 2002, 21:978-979.
414. Licensure of a meningococcal conjugate vaccine for children aged 2 through 10 years and updated booster dose guidance for adolescents and other persons at increased risk for meningococcal disease: Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morb Mortal Wkly Rep 2011, 60:1018-1019.
415. Halperin S.A., Gupta A., Jeanfreau R., et al. Comparison of the safety and immunogenicity of an investigational and a licensed quadrivalent meningococcal conjugate vaccine in children 2-10 years of age. Vaccine 2010, 28:7865-7872.
416. Jackson L.A., Baxter R., Reisinger K., et al. Phase III comparison of an investigational quadrivalent meningococcal conjugate vaccine with the licensed meningococcal ACWY conjugate vaccine in adolescents. Clin Infect Dis 2009, 49:e1-10.
417. Snape M.D., Perrett K.P., Ford K.J., et al. Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial. JAMA 2008, 299:173-184.
418. Halperin S.A., Diaz-Mitoma F., Dull P., et al. Safety and immunogenicity of an investigational quadrivalent meningococcal conjugate vaccine after one or two doses given to infants and toddlers. Eur J Clin Microbiol Infect Dis 2010, 29:259-267.
419. Updated recommendation from the Advisory Committee on Immunization Practices (ACIP) for revaccination of persons at prolonged increased risk for meningococcal disease. MMWR Morb Mortal Wkly Rep 2009, 58:1042-1043.
420. Gill C.J., Baxter R., Anemona A., et al. Persistence of immune responses after a single dose of Novartis meningococcal serogroup A, C, W-135 and Y CRM-197 conjugate vaccine (Menveo(R)) or Menactra(R) among healthy adolescents. Hum Vaccin 2010, 6:881-887.
421. Fijen C.A., Kuijper E.J., Drogari-Apiranthitou M., et al. Protection against meningococcal serogroup ACYW disease in complement-deficient individuals vaccinated with the tetravalent meningococcal capsular polysaccharide vaccine. Clin Exp Immunol 1998, 114:362-369.
422. Balmer P., Falconer M., McDonald P., et al. Immune response to meningococcal serogroup C conjugate vaccine in asplenic individuals. Infect Immun 2004, 72:332-337.
423. Siberry G.K., Williams P.L., Lujan-Zilbermann J., et al. Phase I/II, open-label trial of safety and immunogenicity of meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine in human immunodeficiency virus-infected adolescents. Pediatr Infect Dis J 2010, 29:391-396.
424. Macneil J.R., Cohn A.C., Zell E.R., et al. Early estimate of the effectiveness of quadrivalent meningococcal conjugate vaccine. Pediatr Infect Dis J 2011, 30:451-455.
425. Jackson L.A., Jacobson R.M., Reisinger K.S., et al. A randomized trial to determine the tolerability and immunogenicity of a quadrivalent meningococcal glycoconjugate vaccine in healthy adolescents. Pediatr Infect Dis J 2009, 28:86-91.
426. Centers for Disease Control and Prevention Guillain-Barré syndrome among recipients of Menactra meningococcal conjugate vaccine: United States, June-July 2005. MMWR Morb Mortal Wkly Rep 2005, 54:1023-1025.
427. Willison H.J. The immunobiology of Guillain-Barré syndromes. J Peripher Nerv Syst 2005, 10:94-112.
428. Godschalk P.C., Heikema A.P., Gilbert M., et al. The crucial role of Campylobacter jejuni genes in anti-ganglioside antibody induction in Guillain-Barré syndrome. J Clin Invest 2004, 114:1659-1665.
429. Marks J.S., Halpin T.J. Guillain-Barré syndrome in recipients of A/New Jersey influenza vaccine. JAMA 1980, 243:2490-2494.
430. Cho B.H., Clark T.A., Messonnier N.E., et al. MCV vaccination in the presence of vaccine-associated Guillain-Barré syndrome risk: a decision analysis approach. Vaccine 2010, 28:817-822.
431. Revised recommendations of the Advisory Committee on Immunization Practices to vaccinate all persons aged 11-18 years with meningococcal conjugate vaccine. MMWR Morb Mortal Wkly Rep 2007, 56:794-795.
432. De Wals P., Deshaies P., De Serres G., et al. Risk and prevention of meningococcal disease among education workers: a review. Can J Infect Dis 2004, 15:89-93.
433. Kantor E., Luxenberg J.S., Lucas A.H., et al. Phase I study of the immunogenicity and safety of conjugated Haemophilus influenzae type b vaccines in the elderly. Vaccine 1997, 15:129-132.
434. Lottenbach K.R., Granoff D.M., Barenkamp S.J., et al. Safety and immunogenicity of Haemophilus influenzae type B polysaccharide or conjugate vaccines in an elderly adult population. J Am Geriatr Soc 2004, 52:1883-1887.
435. Goldblatt D., Southern J., Andrews N., et al. The immunogenicity of 7-valent pneumococcal conjugate vaccine versus 23-valent polysaccharide vaccine in adults aged 50-80 years. Clin Infect Dis 2009, 49:1318-1325.
436. Jackson L.A., Neuzil K.M., Nahm M.H., et al. Immunogenicity of varying dosages of 7-valent pneumococcal polysaccharide-protein conjugate vaccine in seniors previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. Vaccine 2007, 25:4029-4037.
437. Letson G.W., Little J.R., Ottman J., et al. Meningococcal vaccine in pregnancy: an assessment of infant risk. Pediatr Infect Dis J 1998, 17:261-263.
438. McCormick J.B., Gusmao H.H., Nakamura S., et al. Antibody response to serogroup A and C meningococcal polysaccharide vaccines in infants born of mothers vaccinated during pregnancy. J Clin Invest 1980, 65:1141-1144.
439. de Andrade Carvalho A., Giampaglia C.M., Kimura H., et al. Maternal and infant antibody response to meningococcal vaccination in pregnancy. Lancet 1977, 2:809-811.
440. Ward J.I., Cherry J.D., Chang S.J., et al. Efficacy of an acellular pertussis vaccine among adolescents and adults. N Engl J Med 2005, 353:1555-1563.
441. Garland S.M., Hernandez-Avila M., Wheeler C.M., et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007, 356:1928-1943.
442. Giuliano A.R., Palefsky J.M., Goldstone S., et al. Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. N Engl J Med 2011, 364:401-411.
443. Arguedas A., Soley C., Loaiza C., et al. Safety and immunogenicity of one dose of MenACWY-CRM, an investigational quadrivalent meningococcal glycoconjugate vaccine, when administered to adolescents concomitantly or sequentially with Tdap and HPV vaccines. Vaccine 2010, 28:3171-3179.
444. Harrison L.H., Mohan N., Kirkpatrick P. Meningococcal group A, C, Y and W-135 conjugate vaccine. Nat Rev Drug Discov 2010, 9:429-430.
445. Syncope after vaccination United States, January 2005-July 2007. MMWR Morb Mortal Wkly Rep 2008, 57:457-460.
446. General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011, 60:1-64.
447. Harrison L.H., Pelton S.I., Wilder-Smith A., et al. The Global Meningococcal Initiative: recommendations for reducing the global burden of meningococcal disease. Vaccine 2011, 29:3363-3371.
448. Deghmane A.E., Parent du Chatelet I., Szatanik M., et al. Emergence of new virulent Neisseria meningitidis serogroup C sequence type 11 isolates in France. J Infect Dis 2010, 202:247-250.
449. Thomas H.L., Andrews N., Trotter C., et al. Meningococcal C booster not recommended by evidence. BMJ 2008, 337:a1139.
450. Miller M.A., Wenger J., Rosenstein N., et al. Evaluation of meningococcal meningitis vaccination strategies for the meningitis belt in Africa. Pediatr Infect Dis J 1999, 18:1051-1059.
451. Jodar L., LaForce F.M., Ceccarini C., et al. Meningococcal conjugate vaccine for Africa: a model for development of new vaccines for the poorest countries. Lancet 2003, 361:1902-1904.
452. Bishai D.M., Champion C., Steele M.E., et al. Product development partnerships hit their stride: lessons from developing a meningitis vaccine for Africa. Health Aff (Millwood) 2011, 30:1058-1064.
453. Forgor A.A., Leimkugel J., Hodgson A., et al. Emergence of W135 meningococcal meningitis in Ghana. Trop Med Int Health 2005, 10:1229-1234.
454. Nathan N., Rose A.M., Legros D., et al. Meningitis serogroup W135 outbreak, Burkina Faso, 2002. Emerg Infect Dis 2007, 13:920-923.
455. Koumare B., Ouedraogo-Traore R., Sanou I., et al. The first large epidemic of meningococcal disease caused by serogroup W135, Burkina Faso, 2002. Vaccine 2007, 25(Suppl. 1):A37-A41.
456. Lee C.H., Kuo W.C., Beri S., et al. Preparation and characterization of an immunogenic meningococcal group A conjugate vaccine for use in Africa. Vaccine 2009, 27:726-732.
457. LaForce F.M., Konde K., Viviani S., et al. The Meningitis Vaccine Project. Vaccine 2007, 25(Suppl. 1):A97-100.
458. Sow S.O., Okoko B.J., Diallo A., et al. Immunogenicity and safety of a meningococcal A conjugate vaccine in Africans. N Engl J Med 2011, 364:2293-2304.
459. LaForce F.M., Okwo-Bele J.M. Eliminating epidemic group A meningococcal meningitis in Africa through a new vaccine. Health Aff (Millwood) 2011, 30:1049-1057.
460. LaForce F.M., Ravenscroft N., Djingarey M., et al. Epidemic meningitis due to group A Neisseria meningitidis in the African meningitis belt: a persistent problem with an imminent solution. Vaccine 2009, 27(Suppl. 2):B13-B19.
461. Nicolas P., Norheim G., Garnotel E., et al. Molecular epidemiology of Neisseria meningitidis isolated in the African meningitis belt between 1988 and 2003 shows dominance of sequence type 5 (ST-5) and ST-11 complexes. J Clin Microbiol 2005, 43:5129-5135.
462. Njanpop-Lafourcade B.M., Parent du Chatelet I., Sanou O., et al. The establishment of Neisseria meningitidis serogroup W135 of the clonal complex ET-37/ST-11 as an epidemic clone and the persistence of serogroup A isolates in Burkina Faso. Microbes Infect 2005, 7:645-649.
463. Pollard A.J., Ochnio J., Ho M., et al. Disease susceptibility to ST11 complex meningococci bearing serogroup C or W135 polysaccharide capsules, North America. Emerg Infect Dis 2004, 10:1812-1815.
464. von Gottberg A., du Plessis M., Cohen C., et al. Emergence of endemic serogroup W135 meningococcal disease associated with a high mortality rate in South Africa. Clin Infect Dis 2008, 46:377-386.
465. Oster P., Lennon D., O'Hallahan J., et al. MeNZB: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain. Vaccine 2005, 23:2191-2196.
466. Holst J., Feiring B., Naess L.M., et al. The concept of "tailor-made", protein-based, outer membrane vesicle vaccines against meningococcal disease. Vaccine 2005, 23:2202-2205.
467. Finne J., Leinonen M., Makela P.H. Antigenic similarities between brain components and bacteria causing meningitis: implications for vaccine development and pathogenesis. Lancet 1983, 2:355-357.
468. Stein D.M., Robbins J., Miller M.A., et al. Are antibodies to the capsular polysaccharide of Neisseria meningitidis group B and Escherichia coli K1 associated with immunopathology?. Vaccine 2006, 24:221-228.
469. Tondella M.L., Popovic T., Rosenstein N.E., et al. Distribution of Neisseria meningitidis serogroup B serosubtypes and serotypes circulating in the United States. The Active Bacterial Core Surveillance Team. J Clin Microbiol 2000, 38:3323-3328.
470. Holst J. Strategies for development of universal vaccines against meningococcal serogroup B disease: the most promising options and the challenges evaluating them. Hum Vaccin 2007, 3:290-294.
471. Russell J.E., Jolley K.A., Feavers I.M., et al. PorA variable regions of Neisseria meningitidis. Emerg Infect Dis 2004, 10:674-678.
472. Sacchi C.T., Whitney A.M., Popovic T., et al. Diversity and prevalence of PorA types in Neisseria meningitidis serogroup B in the United States, 1992-1998. J Infect Dis 2000, 182:1169-1176.
473. Nokleby H., Aavitsland P., O'Hallahan J., et al. Safety review: two outer membrane vesicle (OMV) vaccines against systemic Neisseria meningitidis serogroup B disease. Vaccine 2007, 25:3080-3084.
474. Holst J., Martin D., Arnold R., et al. Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis. Vaccine 2009, 27(Suppl. 2):B3-12.
475. O'Hallahan J., McNicholas A., Galloway Y., et al. Delivering a safe and effective strain-specific vaccine to control an epidemic of group B meningococcal disease. N Z Med J 2009, 122:48-59.
476. Kelly C., Arnold R., Galloway Y., et al. A prospective study of the effectiveness of the New Zealand meningococcal B vaccine. Am J Epidemiol 2007, 166:817-823.
477. Arnold R., Galloway Y., McNicholas A., et al. Effectiveness of a vaccination programme for an epidemic of meningococcal B in New Zealand. Vaccine 2011, 29:7100-7106.
478. Claassen I., Meylis J., van der Ley P., et al. Production, characterization and control of a Neisseria meningitidis hexavalent class 1 outer membrane protein containing vesicle vaccine. Vaccine 1996, 14:1001-1008.
479. van der Ley P., van der Biezen J., Poolman J.T. Construction of Neisseria meningitidis strains carrying multiple chromosomal copies of the porA gene for use in the production of a multivalent outer membrane vesicle vaccine. Vaccine 1995, 13:401-407.
480. Van Der Ley P., Poolman J.T. Construction of a multivalent meningococcal vaccine strain based on the class 1 outer membrane protein. Infect Immun 1992, 60:3156-3161.
481. de Kleijn E.D., de Groot R., Labadie J., et al. Immunogenicity and safety of a hexavalent meningococcal outer-membrane-vesicle vaccine in children of 2-3 and 7-8 years of age. Vaccine 2000, 18:1456-1466.
482. Cartwright K., Morris R., Rumke H., et al. Immunogenicity and reactogenicity in UK infants of a novel meningococcal vesicle vaccine containing multiple class 1 (PorA) outer membrane proteins. Vaccine 1999, 17:2612-2619.
483. Sette A., Rappuoli R. Reverse vaccinology: developing vaccines in the era of genomics. Immunity 2010, 33:530-541.
484. Rinaudo C.D., Telford J.L., Rappuoli R., et al. Vaccinology in the genome era. J Clin Invest 2009, 119:2515-2525.
485. Moriel D.G., Scarselli M., Serino L., et al. Genome-based vaccine development: a short cut for the future. Adv Exp Med Biol 2009, 655:81-89.
486. Pizza M., Scarlato V., Masignani V., et al. Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science 2000, 287:1816-1820.
487. Fletcher L.D., Bernfield L., Barniak V., et al. Vaccine potential of the Neisseria meningitidis 2086 lipoprotein. Infect Immun 2004, 72:2088-2100.
488. Murphy E., Andrew L., Lee K.L., et al. Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis. J Infect Dis 2009, 200:379-389.
489. Dunphy K.Y., Beernink P.T., Brogioni B., et al. Effect of factor H-binding protein sequence variation on factor H binding and survival of Neisseria meningitidis in human blood. Infect Immun 2011, 79:353-359.
490. Welsch J.A., Ram S., Koeberling O., et al. Complement-dependent synergistic bactericidal activity of antibodies against factor H-binding protein, a sparsely distributed meningococcal vaccine antigen. J Infect Dis 2008, 197:1053-1061.
491. Beernink P.T., Welsch J.A., Bar-Lev M., et al. Fine antigenic specificity and cooperative bactericidal activity of monoclonal antibodies directed at the meningococcal vaccine candidate factor H-binding protein. Infect Immun 2008, 76:4232-4240.
492. Jiang H.Q., Hoiseth S.K., Harris S.L., et al. Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease. Vaccine 2010, 28:6086-6093.
493. Seib K.L., Brunelli B., Brogioni B., et al. Characterization of diverse subvariants of the meningococcal factor H (fH) binding protein for their ability to bind fH, to mediate serum resistance, and to induce bactericidal antibodies. Infect Immun 2011, 79:970-981.
494. Pajon R., Fergus A.M., Koeberling O., et al. Meningococcal factor H binding proteins in epidemic strains from Africa: implications for vaccine development. PLoS Negl Trop Dis 2011, 5:e1302. doi:10.1371/journal.pntd.0001302.
495. Vu D.M., Wong T.T., Granoff D.M. Cooperative serum bactericidal activity between human antibodies to meningococcal factor H binding protein and Neisserial heparin binding antigen. Vaccine 2011, 29:1968-1973.
496. Giuliani M.M., Adu-Bobie J., Comanducci M., et al. A universal vaccine for serogroup B meningococcus. Proc Natl Acad Sci U S A 2006, 103:10834-10839.
497. Serruto D., Spadafina T., Ciucchi L., et al. Neisseria meningitidis GNA2132, a heparin-binding protein that induces protective immunity in humans. Proc Natl Acad Sci U S A 2010, 107:3770-3775.
498. Capecchi B., Adu-Bobie J., Di Marcello F., et al. Neisseria meningitidis NadA is a new invasin which promotes bacterial adhesion to and penetration into human epithelial cells. Mol Microbiol 2005, 55:687-698.
499. Comanducci M., Bambini S., Brunelli B., et al. NadA, a novel vaccine candidate of Neisseria meningitidis. J Exp Med 2002, 195:1445-1454.
500. Bambini S., Muzzi A., Olcen P., et al. Distribution and genetic variability of three vaccine components in a panel of strains representative of the diversity of serogroup B meningococcus. Vaccine 2009, 27:2794-2803.
501. Snape M.D., Dawson T., Oster P., et al. Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial. Pediatr Infect Dis J 2010, 29:e71-e79.
502. Findlow J., Borrow R., Snape M.D., et al. Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy. Clin Infect Dis 2010, 51:1127-1137.
503. Richmond P., Marshall H., Nissen M.D., et al. A randomized, observer-blinded, active control, phase 1 trial of meningococcal serogroup B rLP2086 vaccine in healthy children and adolescents aged 8 to 14 years 2008.
504. Marshall H., Nissen M.D., Richmond P., et al. A randomized, placebo-controlled, double-blind, phase 1 trial of ascending doses of meningococcal group B rLP2086 vaccine in healthy adults 2008.
505. Jansen K.U., McNeil L.K., Dragalin V., et al. Bivalent recombinant LP2086 vaccine to provide broad protection against Neisseria meningitidis B disease: immunological correlates of protection and how to assess coverage against invasive MnB strains 2008.
506. Richmond P.C., Marshall H.S., Nissen M.D. Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial. Lancet Infectious Diseases 2012, doi:10.1016/S1473-3099(12)70087-7.
507. Toneatto D., Ismaili S., Ypma E., et al. The first use of an investigational multicomponent meningococcal serogroup B vaccine (4CMenB) in humans. Hum Vaccin 2011, 7:646-653.
508. Toneatto D., Oster P., Deboer A.C., et al. Early clinical experience with a candidate meningococcal B recombinant vaccine (rMenB) in healthy adults. Hum Vaccin 2011, 7:781-791.
509. Weynants V.E., Feron C.M., Goraj K.K., et al. Additive and synergistic bactericidal activity of antibodies directed against minor outer membrane proteins of Neisseria meningitidis. Infect Immun 2007, 75:5434-5442.
510. Santolaya M.E., O'Ryan M.L., Valenzuela M.T., et al. Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study. Lancet 2012, 379:617-624.
511. Gossger N., Snape M.D., Yu L.M., et al. Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial. JAMA 2012, 307:573-582.
512. Cohn A.C., Messonnier N.E. Inching toward a serogroup B meningococcal vaccine for infants. JAMA 2012, 307:614-615.
513. Martin D., Cadieux N., Hamel J., et al. Highly conserved Neisseria meningitidis surface protein confers protection against experimental infection. J Exp Med 1997, 185:1173-1183.
514. Halperin S.A., Langley J.M., Smith B., et al. Phase 1 first-in-human studies of the reactogenicity and immunogenicity of a recombinant meningococcal NspA vaccine in healthy adults. Vaccine 2007, 25:450-457.
515. Beernink P.T., Shaughnessy J., Braga E.M., et al. A meningococcal factor H binding protein mutant that eliminates factor H binding enhances protective antibody responses to vaccination. J Immunol 2011, 186:3606-3614.
516. Hou V.C., Koeberling O., Welsch J.A., et al. Protective antibody responses elicited by a meningococcal outer membrane vesicle vaccine with overexpressed genome-derived neisserial antigen 1870. J Infect Dis 2005, 192:580-590.
517. Koeberling O., Seubert A., Granoff D.M. Bactericidal antibody responses elicited by a meningococcal outer membrane vesicle vaccine with overexpressed factor H-binding protein and genetically attenuated endotoxin. J Infect Dis 2008, 198:262-270.
518. Koeberling O., Giuntini S., Seubert A., et al. Meningococcal outer membrane vesicle vaccines derived from mutant strains engineered to express factor H binding proteins from antigenic variant groups 1 and 2. Clin Vaccine Immunol 2009, 16:156-162.
519. Steeghs L., Tommassen J., Leusen J.H., et al. Teasing apart structural determinants of "toxicity" and "adjuvanticity": implications for meningococcal vaccine development. J Endotoxin Res 2004, 10:113-119.
520. Jursnich V.A., Fraser S.E., Held L.I., et al. Defective gap-junctional communication associated with imaginal disc overgrowth and degeneration caused by mutations of the dco gene in Drosophila. Dev Biol 1990, 140:413-429.
521. Koeberling O., Welsch J.A., Granoff D.M. Improved immunogenicity of a H44/76 group B outer membrane vesicle vaccine with over-expressed genome-derived neisserial antigen 1870. Vaccine 2007, 25:1912-1920.
522. Koeberling O., Delany I., Granoff D.M. A critical threshold of meningococcal factor H binding protein expression is required for increased breadth of protective antibodies elicited by native outer membrane vesicle vaccines. Clin Vaccine Immunol 2011, 18:736-742.
523. Koeberling O., Seubert A., Santos G., et al. Immunogenicity of a meningococcal native outer membrane vesicle vaccine with attenuated endotoxin and over-expressed factor H binding protein in infant rhesus monkeys. Vaccine 2011, 29:4728-4734.